cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE AND USES THEREOF

Abstract: The invention features methods for diagnosing subjects at risk for or suffering from a disease or disorder, such as a psychosis. Methods are also provided for selecting a preferred therapy for a particular subject or group of subjects.

Description: cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE AND USES THEREOF BACKGROUND OF THE INVENTION (a) Field ofthe Invention The invention relates to a cDNA probe for human methylenetetrahydrofolate reductase (MTHFR), and its uses, (b) Description of Prior Art Folic acid derivatives are coenzymes for several critical single-carbon transfer reactions, including reactions in the biosynthesis of purines, thymidylate and methionine. Methylenetetrahydrofolate reductase (MTHFR; EC 1.5.1.20) catalyses the NADPH- linked reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co- substrate for methylation of homocysteine to methionine. The porcine liver enzyme, a flavoprotein, has been purified to homogeneity; it is a homodimer of 77-kDa subunits. Partial proteolysis ofthe porcine peptide has revealed two spatially distinct domains: an N-terminal domain of 40 kDa and a C-terminal domain of 37 kDa. The latter domain contains the binding site for the allosteric regulator S-adenosylmethionine. Hereditary deficiency of MTHFR, an autosomal recessive disorder, is the most common inborn error of folic acid metabolism. A block in the production of methyltetrahydrofolate leads to elevated homocysteine with low to normal levels of methionine. Patients with severe deficiencies of MTHFR (0 -20% activity in fibroblasts) can have variable phenotypes. Developmental delay, mental retardation, motor and gait abnormalities, peripheral neuropathy, seizures and psychiatric disturbances have been reported in this group, although at least one patient with severe MTHFR deficiency was asymptomatic. Pathologic changes in the severe form include the vascular changes that have been found in other conditions with elevated homocysteine, as well as reduced neurotransmitter and methionine levels in the CNS. A milder deficiency of MTHFR (35- 50% activity) has been described in patients with coronary artery disease (see below). Genetic heterogeneity is likely, considering the diverse clinical features, the variable levels of enzyme activity, and the differential heat inactivation profiles ofthe reductase in patients' cells. Coronary artery disease (CAD) accounts for 25% of deaths of Canadians. Cardiovascular risk factors (male sex, family history, smoking, hypertension, dyslipoproteinemia and diabetes) account for approximately 60 to 70% ofthe ability to discriminate CAD patients from healthy subjects. Elevated plasma homocysteine has also been shown to be an independent risk factor for cardiovascular disease. Homocysteine is a sulfhydryl-containing amino acid that is formed by the demethylation of methionine. It is normally metabolized to cysteine (transsulfuration) or re-methylated to methiomne. Inborn errors of metabolism (as in severe MTHFR deficiency) causing extreme elevations of homocysteine in plasma, with homocystinuria, are associated with premature vascular disease and widespread arterial and venous thrombotic phenomena. Milder elevations of plasma homocysteine (as in mild MTHFR deficiency) have been associated with the development of peripheral vascular disease, cerebro vascular disease and premature CAD. Homocysteine remethylation to methionine requires the folic acid intermediate, 5-methyltetrahydrofolate, which is produced from 5,10-methylenetet- rahydrofolate folate through the action of 5,10-methylenetetrahydrofolate reductase (MTHFR). Deficiency of MTHFR results in an inability to metabolize homocysteine to methionine; elevated plasma homocysteine and decreased methionine are the metabolic consequences ofthe block. Severe deficiencies of MTHFR (less than 20% of activity of controls) as described above, are associated with early-onset neurologic symptoms (mental retardation, peripheral neuropathy, seizures, etc.) and with atherosclerotic changes and thromboembolism. Milder deficiencies of MTHFR (35-50% of activity of controls), with a thermolabile form ofthe enzyme, are seen in patients with cardiovascular disease without obvious neurologic abnormalities. In a survey of 212 patients with proven coronary artery disease, the thermolabile form of MTHFR was found in 17% ofthe CAD group and 5% of controls. In a subsequent report on 339 subjects who underwent coronary angiography, a correlation was found between thermolabile MTHFR and the degree of coronary artery stenosis. Again, traditional risk factors (age, sex, smoking, hypertension, etc.) were not significantly associated with thermolabile MTHFR. All the studies on MTHFR were performed by enzymatic assays of MTHFR in lymphocytes, with measurements of activity before and after heat treatment to determine thermolability ofthe enzyme. Since 5-methyltetrahydrofolate, the product ofthe MTHFR reaction, is the primary form of circulatory folate, a deficiency in MTHFR might lead to other types of disorders. For example, periconceptual folate administration to women reduces the occurrence and recurrence of neural tube defects in their offspring. Neural tube defects are a group of developmental malformations (meningomyelocele, anencephaly, and encephalocele) that arise due to failure of closure ofthe neural tube. Elevated levels of plasma homocysteine have been reported in mothers of children with neural tube defects. The elevated plasma homocysteine could be due to a deficiency of MTHFR, as described above for cardiovascular disease. Neuroblastomas are tumors derived from neural crest cells. Many of these tumors have been reported to have deletions of human chromosome region lp36, the region ofthe genome to which MTHFR has been mapped. It is possible that MTHFR deletions/mutations are responsible for or contribute to the formation of this type of tumor. MTHFR abnormalities may also contribution to the formation of other types of tumors, such as colorectal tumors, since high dietary folate has been shown to be inversely associated with risk of colorectal carcinomas. MTHFR activity is required for homocysteine methylation to methionine. Methionine is necessary for the formation of S-adenosylmethionine, the primary methyl donor for methylation of DNA, proteins, lipids, neurotransmitters, etc. Abnormalities in MTHFR might lead to lower levels of methionine and S-adenosylmethionine, as well as to elevated homocysteine. Disruption of methylation processes could result in a wide variety of conditions, such as neoplasias, developmental anomalies, neurologic disorders, etc. Although the MTHFR gene in Escherichia coli (metF) has been isolated and sequenced, molecular studies ofthe enzyme in higher organisms have been limited without the availability of an eukaryotic cDNA. It would be highly desirable to be provided with a cDNA probe for human methylenetetrahydrofolate reductase (MTHFR). This probe would be used for identification of sequence abnormalities in individuals with severe or mild MTHFR deficiency, including cardiovascular patients and patients with neurologic symptoms or tumors. The probe would also be used in gene therapy, isolation ofthe gene, and expression studies to produce the MTHFR protein. The probe would also provide the amino acid sequence ofthe human MTHFR protein, which would be useful for therapy of MTHFR deficiency by biochemical or pharmacological approaches. It would be highly desirable to be provided with a molecular description of mutations in methylenetetrahydrofolate reductase deficiency. Patients with sequence abnormalities in MTHFR might have different responses to drugs, possibly but not limited to drugs that affect folate metabolism. Therefore, it would be useful to know if these mutations are present before determining the appropriate therapy. The drugs/diseases for which this might be relevant include cancer chemotherapeutic agents, antibiotics, antiepileptic medication, antiarthritic medication, etc. SUMMARY OF THE INVENTION One aim of the present invention is to provide a cDNA probe for human methylenetetrahydrofolate reductase (MTHFR). Another aim ofthe present invention is to provide a molecular description of mutations in methylenetetrahydrofolate reductase deficiency. Another aim ofthe present invention is to provide a nucleic acid and amino acid sequence for human methylenetetrahydrofolate reductase. Another aim ofthe present invention is to provide potential therapy for individuals with methylenetetrahydrofolate reductase deficiency. Another aim ofthe present invention is to provide a system for synthesis of MTHFR protein in vitro. A further aim ofthe present invention is to provide technology/protocol for identification of sequence changes in the MTHFR gene. In accordance with one aspect ofthe present invention, there is provided a cDNA probe for human methylenetetrahydrofolate reductase (MTHFR) gene encoded by a nucleotide sequence as set forth in SEQ ID NO:l or having an amino acid sequence as set forth in SEQ ID NO:2. The probe comprises a nucleotide sequence that hybridizes to the MTHFR nucleotide sequence, or an amino acid sequence that hybridizes to the MTHFR amino acid sequence. In accordance with another aspect ofthe present invention, there is provided a method of diagnosis of methylenetetrahydrofolate reductase (MTHFR) deficiency in a patient with MTHFR deficiency. The method comprises the steps of amplifying a DNA sample obtained from the patient or reverse-transcripting a RNA sample obtained from the patient into a DNA and amplifying the DNA, and analyzing the amplified DNA to determine at least one sequence abnormality with respect to a human MTHFR encoded by a nucleotide sequence as set forth in SEQ ID NO:l or having an amino acid sequence as set forth in SEQ ID NO: 2, the sequence abnormality being indicative of MTHFR deficiency. The sequence abnormality may comprise a mutation selected from a group consisting of 167G/A; 482G/A, 559C/T, 677C/T, 692C/T, 764C/T, 792+1G/A, 985C/T, 1015C/T, 1081C/T, 1298A/C and 1317T/C. The selected mutation may consist of 677C/T. The MTHFR deficiency may be associated with a disease, disorder, or dsyfuntion selected from a group consisting of cardiovascular disorders, cancer, osteoporosis, increased risk of occurrence of a neural tube defect in an offspring of said patient, neurological disorders, disorders influenced by folic acid metabolism, metabolic or endocrine disease, inborn errors of metabolism, inflammation, immune disorders, psychiatric illness, neoplastic disease and other related disorders, and renal disease. The cancer may be selected from a group consisting of neuroblastomas and colorectal carcinomas. The disorder may consist of osteoporosis. In accordance with yet another aspect ofthe present invention, there is provided a method for gene therapy of methylenetetrahydrofolate reductase (MTHFR) deficiency in a patient. The method comprises the steps of producing a recombinant vector for expression of MTHFR under the control of a suitable promoter, the MTHFR being encoded by a nucleotide sequence as set forth in SEQ ID NO:l or having an amino acid sequence as set forth in SEQ ID NO:2, and transfecting the patient with the vector for expression of MTHFR. In accordance with yet another aspect ofthe present invention, there is provided a human methylenetetrahydrofolate reductase (MTHFR) protein encoded by a nucleotide sequence as set forth in SEQ ID NO:l or having an amino acid sequence as set forth in SEQ ID NO:2. In accordance with yet another aspect ofthe present invention, there is provided a recombinant human methylenetetrahydrofolate reductase (MTHFR) protein encoded by a nucleotide sequence as set forth in SEQ ID NO:l or having an amino acid sequence as set forth in SEQ ID NO:2. In accordance with yet another aspect ofthe present invention, there is provided a method of treatment of MTHFR-deficiency in a patient that comprises administering such a MTHFR protein. The MTHFR deficiency may be associated with a cancer. The cancer may be selected from a group consisting of neuroblastomas and colorectal carcinomas. In accordance with yet another aspect ofthe present invention, there is provided a method of preventing an occurrence of a neural tube defect in an offspring of a patient. The method comprises administering to the patient such a MTHFR protein. In accordance with yet another aspect ofthe present invention, there is provided a method for determining drug susceptibility, drug response or drug toxicity of a patient having a methylenetetrahydrofolate reductase (MTHFR) deficiency. The method comprises the steps of amplifying a DNA sample obtained from the patient or reverse- transcripting a RNA sample obtained from the patient into a DNA and amplifying said DNA, analyzing the amplified DNA to determine a sequence abnormality in a MTHFR sequence, the MTHFR sequence being encoded by a nucleotide sequence as set forth in SEQ ID NO: 1 or having an amino acid sequence as set forth in SEQ LD NO:2, and administering the drug to the patient and determining the sequence abnormality associated with the patient susceptibility, response or toxicity to the drug. Further, in human therapeutic approaches, both pharmacokinetics and pharmacodynarnics may be influenced by folic acid metabolism. Pharmacokinetics includes, but is not excluded to, factors such as absorption, distribution, metabolism, and excretion. Other considerations include safety and toxicity. Examples of toxicities from therapeutics include, but are not limited to, blood dyscrasias, cutaneous toxicities, systemic toxicity, CNS toxicity, hepatic toxicity, cardiovascular toxicity, pulmonary toxicity, and renal toxicity. The sequence abnormality may comprise a mutation selected from a group consisting of 167G/A, 482G/A, 559C/T, 677C/T, 692C/T, 764C/T, 792+1G/A, 985C/T, 1015C/T, 1081C/T, 1298A/C and 1317T/C and the drug may be selected from a group consisting of cancer chemotherapeutic agents, antibiotics, antiepileptic agents, antiarthritic agents, and anti-inflammatory agents. Examples of chemotherapeutic agents include alkylating agents (nitrogen mustards, ethylenimines and methylmelamines, alkyl sulfonates, nitrosoureas, triazenes), antimetabolites (folic acid analogs, pyrimidine analogs, purine analogs and related inhibitors), and natural products (vinca alkyloids, epipodophyllotoxins, antibiotics, enzymes, biological response modifiers). Examples of anti-inflammatory agents include non-steroidal anti-inflammatory agents, steroids, antihistaminergics, 5-LO inhibitors, cytokine agonists, and cytokine antagonists. The drug may also include therapies for metabolic or endocrine disease such as hormone agonists and antagonists, intracellular response modifiers, and secretegogues. Other possible drugs include therapies for cardiovasular disease or disorders such as antianemic, antiangina, antiarrythmics, antihypertensives, positive inotropic agents, and antithrombotics. The drug may also be a therapy for an immune disorder, such as immune modulators, immunosuppression agents, and immunostimulation agents. Additionally, any other drug for the treatment of a metabolic disease, inborn errors of metabolism, psychiatric disorders, neoplastic disease and other related disorders, and renal disease is relevant to the invention The MTHFR deficiency may be associated with a disorder selected from a group consisting of cardiovascular disorders, coronary and arterial disorders, neurological disorders, increased risk of occurrence of a neural tube defect in an offspring, cancer, osteoporosis and other disorders influenced by folic acid metabolism. In accordance with yet another aspect ofthe present invention, there is provided a method of treatment of a patient having a cancer comprising the step of inhibiting gene expression for a MTHFR protein or a mRNA produced form the gene. In accordance with yet another aspect ofthe present invention, there is provided a method of treatment of a patient having a cancer comprising the step of inhibiting the MTHFR protein. The use of MTHFR alleles as diagnostic, therapeutic, prognostic, and pharmacogenomic markers may also be applied to neurological disorders such as psychoses and to other diseases and disorders that may be treated with anti-psychotic therapeutics. The presence of particular MTHFR alleles may be used to predict the safety and efficacy of a particular therapy and to select preferred therapies for these subjects. Accordingly, in one aspect, the invention provides a method of diagnosing a psychosis in a subject. This method involves analyzing the MTHFR nucleic acid in a sample obtained from the subject and determining the presence of at least one heterozygous MTHFR mutant allele in the subject that is indicative ofthe subject having the psychosis. In a related aspect, the invention features a method of determining a risk for a psychosis or a propensity for a psychosis in a subject. This method includes analyzing the MTHFR nucleic acid in a sample obtained from said subject and determining the presence of at least one heterozygous MTHFR mutant allele in the subject that is indicative ofthe risk for a psychosis or the propensity for a psychosis in the subject. In another aspect, the invention provides a method of diagnosing a psychosis in a subject. This method involves analyzing the MTHFR nucleic acid in a sample obtained from the subject and determining the presence of a heterozygous MTHFR mutation at position 677 and/or the presence of at least one other MTHFR mutation at a position other than 677. These mutations are indicative ofthe subject haying the psychosis. The invention also provides a related method of diagnosing a risk for a psychosis or a propensity for a psychosis in a subject. This method includes analyzing the MTHFR nucleic acid in a sample obtained from the subject and determining the presence of a heterozygous MTHFR mutation at position 677 and the presence of at least one other MTHFR mutation at a position other than 677. These mutations are indicative ofthe risk for a psychosis or the propensity for a psychosis in the subject. In addition to their use in diagnosing a psychosis or an increased risk for a psychosis, the determination of one or more mutations in an MTHFR allele may also be used to classify subjects into a subgroup for a clinical trial of an anti-psychotic therapy, to determine a preferred anti-psychotic therapy for a subject, or to determine whether the MTHFR mutations are indicative of a response to an anti-psychotic therapy. Accordingly, the invention also provides a method for stratification of subjects involved in a clinical trial of an anti-psychotic therapy. This method involves analyzing the MTHFR nucleic acid in a sample obtained from a subject and determining before, during, or after the clinical trial the presence of at least one MTHFR mutant allele in the subject that places the subject into a subgroup for the clinical trial. In one preferred embodiment, the anti-psychotic therapy is a therapy for schizophrenia. In another aspect, the invention provides a method for selecting a therapy for a subject suffering from a psychosis. This method include analyzing the MTHFR nucleic acid in a sample obtained from the subject and determining the presence of at least one MTHFR mutant allele in the subject that is indicative ofthe safety or efficacy ofthe therapy. In yet another aspect, the invention features a method for determining whether a mutant MTHFR allele is indicative of a response to a therapy for a psychosis. This method includes (a) determining whether the response of a first subject or set of subjects at increased risk for or diagnosed with the psychosis differs from the response of a second subject or set of subjects at increased risk for or diagnosed with the psychosis, (b) analyzing the MTHFR nucleic acid in a sample obtained from the first and second subjects or sets of subjects, and (c) determining whether at least one MTHFR mutant allele differs between the first and second subjects or sets of subjects. If the MTHFR mutant allele is correlated to a response to the therapy, the mutant allele is determined to be indicative ofthe safety or efficacy ofthe therapy. The invention also provides a method for preventing, delaying, or treating a psychosis in a subject. This method includes (a) analyzing the MTHFR nucleic acid in a sample obtained from the subject, (b) determining the presence of at least one MTHFR mutant allele in the subject that is predictive ofthe safety or efficacy of at least one anti- psychotic therapy, (c) determining a preferred therapy for the subject, and (d) administering the preferred therapy to the subject. In another aspect, the invention provides a pharmaceutical composition including a compound which has a differential effect in subjects having at least one copy of a particular MTHFR allele and has a pharmaceutically acceptable carrier, excipient, or diluent. This compound is preferentially effective to treat a subject having the particular MTHFR allele. In a preferred embodiment, the composition is adapted to be preferentially effective based on the unit dosage, presence of additional active components, complexing ofthe compound with stabilizing components, or inclusion of components enhancing delivery or slowing excretion ofthe compound. In another preferred embodiment, the compound is deleterious to subjects having at least one copy ofthe particular MTHFR allele or in subjects not having at least one copy ofthe particular MTHFR allele, but not in both. In yet another preferred embodiment, the subject suffers from a disease or condition selected from the group consisting of amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, psychoses, and stroke. In still another preferred embodiment, the pharmaceutical composition is subject to a regulatory restriction or recommendation for use of a diagnostic test determining the presence or absence of at least one particular MTHFR allele. In another preferred embodiment, the pharmaceutical composition is subject to a regulatory limitation or recommendation restricting or recommending restriction ofthe use ofthe pharmaceutical composition to subjects having at least one particular MTHFR allele. In yet another preferred embodiment, the pharmaceutical composition is subject to a regulatory limitation or recommendation indicating the pharmaceutical composition is not to be used in subjects having at least one particular MTHFR allele. In still another preferred embodiment, the pharmaceutical composition is packaged, and the packaging includes a label or insert restricting or recommending the restriction ofthe use ofthe pharmaceutical composition to subjects having at least one particular MTHFR allele. In yet another embodiment, the pharmaceutical composition is packaged, and the packaging includes a label or insert requiring or recommending the use of a test to determine the presence or absence of at least one particular MTHFR allele in a subject. Preferably, the compound is an anti-psychotic therapy, such as a therapy for schizophrenia. In preferred embodiments of each ofthe aspects ofthe invention, the mutant MTHFR allele encodes an MTHFR protein with reduced activity or reduced thermal stability. It is also contemplated that the MTHFR protein may have a reduced half-life. Preferably, the MTHFR mutation is a missense mutation. Preferred MTHFR mutations include a G/A mutation at position 167, a G/A mutation at position 482, a C/T mutation a position 559, a C/T mutation at position 677, a C/T mutation at position 692, a C/T mutation at position 764, a G/A mutation at position 792+1, a C/T mutation at position 985, a C/T mutation at position 1015, a C/T mutation at position 1081, an A/C mutation at position 1298, and a T/C mutation at position 1317. It is also contemplated that the mutations at these positions may involve changes to other nucleotides. In other preferred embodiments, the subject has at least two MTHFR mutant alleles. Preferably the two or more mutant MTHFR alleles have at least one ofthe following: a G/A mutation at position 167, a G/A mutation at position 482, a C/T mutation a position 559, a C/T mutation at position 677, a C/T mutation at position 692, a C/T mutation at position 764, a G/A mutation at position 792+1, a C/T mutation at position 985, a C/T mutation at position 1015, a C/T mutation at position 1081, an A/C mutation at position 1298, or a T/C mutation at position 1317. In yet other preferred embodiments, the MTHFR mutation results in a change in the amino acid at position 226 ofthe encoded protein from alanine found in wild-type MTHFR to any other amino acid, including valine or residues other than valine. In still other preferred embodiments, the mutation results in a change in amino acid 433 ofthe encoded protein from glutamic acid to any other amino acid, including alanine or residues other than alanine. When two mutations are present at different nucleotide positions, the mutations may be in the same or different MTHFR alleles. The MTHFR mutation may, without limitation, also be an insertion, deletion, or frameshift mutation. Preferably, the psychosis being diagnosed or treated is schizophrenia. The psychosis may also be any other psychosis such as manic-depressive disease, depression with psychotic features, organic psychotic disorders, psychosis in alcohol or drug intoxication, postinfection psychosis, pos artum psychosis, senile psychosis, traumatic psychosis, manic-depressive psychosis, psychosis from toxic agents, and acute idiopathic psychotic illnesses. The use of MTHFR alleles as diagnostic, therapeutic, prognostic, and pharmacogenomic markers may also be applied to other neurological disorders. Examples of neurological disorders include, but are not limited to, mood disorders, neurodegenerative diseases, cognitive disorders, seizure disorders such as epilepsy, headaches such as migraines, pain associated with the central nervous system, demyelinating diseases, spasticity, neural tube defects, neurofibromatosis, and ischemic cerebrovascular diseases such as thrombotic and hemorrhagic strokes. Mood disorders include but are not excluded to conditions such as unipolar depression, bipolar depression and anxiety. Examples of neurodegenerative diseases include amyotrophic lateral sclerosis, Parkinson's disease, acquired or symptomatic parkinsonism, Huntington's disease, and heredodegenerative disease. Examples of cognitive disorders include dementia, dementia ofthe Alzheimer's type, vascular dementia, multi-infarct dementia and posttraumatic dementia. Demyelinating diseases consist of diseases such as the following: multiple sclerosis (MS), Marburg and Balo forms of MS, neuromyelitis optica, perivenous encephalitits, acute disseminated encephalomyelitits, and acute necotizing hemmorhhagic encephalitis. The methods ofthe invention may also be applied to non-psychiatric conditions for which anti-psychotic drugs are used. Examples of these conditions include nausea, vomiting, movement disorders associated with neurodegenerative diseases such as Huntington's disease and Tourette's syndrome, pruritis, and chronic hiccough. Cardiovascular disorders, cancers, neoplastic disease and other related disorders, osteoporosis, neural tube defects, neurological disorders, disorders influenced by folic acid metabolism, metabolic or endocrine disease, inborn errors of metabolism, inflammation, immune disorders, psychiatric illness, and renal disease are also relevant to these methods. It is to be understood that the methods ofthe invention may be applied to any other diseases or disorders. Examples of other diseases or disorders may include those that are indirectly or directly affected by an increase or decrease in MTHFR activity, homocysteine levels, methionine levels, S-adenosylmethionine activity, or methylation. The therapies relevant to the methods ofthe present invention include all clinically used therapies and therapies in preclinical or clinical development for the aforementioned diseases and disorders. Preferred therapies include the therapies listed in databases such as Life Cycle, R&D Focus, IMS World Publications, London UK or in any other database of therapies that are in development and/or that are FDA approved. Preferred anti-psychotic therapies include conventional neuroleptics such as phenothiazines (e.g. chlorpromazine), thioxanthenes (e.g. thiothixene), butyrophenones (e.g. haloperidol, one ofthe most useful conventional anti-psychotics), dibenzoxazepines, dibenzodiazepines, diphenylbutylpiperidines, and other heterocyclic compounds. Preferred atypical neuroleptics include compounds such as clozaril, risperidone, olanzapine, quetiapine, ziprasidone, amisulpride, sertindole, and iloperidone. Additionally, anti-psychotic therapies, such as loxapine, may have pharmacology intermediate between that of conventional and atypical neuroleptics. In preferred embodiments, the treatment or prevention of a neurological disease includes administration of one or more therapeutically active compounds that bind to a dopamine, histamine, muscarinic cholinergic, α-adrenergic, or serotonin receptors. Examples of other pharmaceutically active compounds which may be used as anti- psychotics include synthetic organic molecules, naturally occurring organic molecules, nucleic acid molecules, biosynthetic proteins or peptides, naturally occurring peptides or proteins, and modified naturally occurring peptides or proteins. In preferred embodiments, the preferred therapy consists of an altered dose regime compared to other clinically used dose regimes or to the administration of a combination of therapeutics. It is also contemplated that the preferred therapy may consist of other medical treatments, such as surgical procedures, electroconvulsive therapy, or psychotherapy. Examples of psychotherapies include dynamic psychotherapy, cognitive-behavioral therapy, interpersonal therapy, behavioral therapy, group psychotherapy, and family therapy. For the administration of a therapeutically active compound to a subject, any mode of administration or dosing regime may be used. It is to be understood that for any particular subject, specific dosage regimes should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration ofthe compositions. Descriptions of clinically used therapies (for example, for psychosis) and guidelines for their use are readily available in common references such as the Physicians Desk Reference (PDR). Additionally, therapeutics are described and listed in medical, pharmacy, and pharmacology journals and textbooks, such as Goodman and Gilman 's The Pharamcological Basis of Therapeutics, (Hardman and Limbird (eds.) Ninth Edition, McGraw-Hill, New York, 1996). Additional information on FDA approved therapeutics and therapies in clinical trials for particular indications, diseases, or disorders may be easily found in electronic databases available through subscription and pharmaceutical company information. By "preferred therapy" is meant a therapy for a disease, disorder, or dysfunction that is efficacious, safe, and/or has reduced toxicity compared to another therapy for the disease or disorder. The preferred therapy selected based on one or more mutations in one or more MTHFR alleles is preferably effective in at least 20, 30, 50, 70, or 90% of the subjects having the MTHFR mutation(s). By "effective" is meant ablates, reduces, or stabilizes symptoms in a subject suffering from a disease, disorder, or dysfunction prevents the onset of symptoms in a subject at risk for a disease, disorder, or dysfuction, or results in a later age-at-onset of symptoms in the subject compared to the average age- at-onset for the corresponding untreated subjects with the same MTHFR mutation(s). The effectiveness ofthe therapy for the treatment of a psychosis may be evaluated based on the Clinical Global Impression (CGI), Diagnostic Interview for Genetic Studies (DIGS), Global Assessment Score (GAS), or Brief Psychiatric Rating Scale (BPRS) using standard procedures. Preferably, the total BPRS score is lowered by 5, more preferably 10, and most preferably 15 points. By "reduced toxicity" is meant lower level of adverse pharmacological or physiological effects. Preferably, the therapy produces clinically unacceptable side-effects in 5, 10, 20, 30, or 50% fewer ofthe subjects having the MTHFR mutations(s) than in subjects who do not have one or ore ofthe MTHFR mutations. A "polymorphism" is intended to mean a mutation or allelic variance present in 1% or more of alleles ofthe general population. A polymorphism is disease-causing when it is present in patients with a disease but not in the general population. However, a polymorphism present both in patients having a disease and in the general population is not necessarily benign. The definition of a disease-causing substitution, as distinct from a benign polymorphism, is based on 3 factors: (1) absence ofthe change in at least 50 independent control chromosomes; (2) presence ofthe amino acid in the bacterial enzyme, attesting to its evolutionary significance and (3) change in amino acid not conservative. Although expression ofthe substitutions is required to formally prove that they are not benign, the criteria above allow us to postulate that the changes described in this report are likely to affect activity. BRIEF DESCRIPTION OF THE DRAWINGS Figs. 1 A to IF illustrate the first cDNA coding sequence (SEQ ID NO: 1 and NO:2) for methylenetetrahydrofolate reductase (MTHFR); Fig. 2 is the alignment of amino acids for human methylenetetrahydrofolate reductase (MTHFR), the metE genes from E. Coli (ΕCOMΕTF), and S. Typhimurium (STYMΕTF), and an unidentified open reading frame in Saccharomyces cerevisiae that is divergently transcribed from an excision repair gene (ysRAD 1 ); Figs. 3 A and 3B illustrate the sequencing and restriction enzyme analysis for the Arg to Ter substitution; Figs. 4 A and 4B illustrate the sequencing and restriction enzyme analysis for the Arg to Gin substitution; Figs. 5 A and 5B illustrate the sequence change and restriction enzyme analysis for the alanine to valine substitution; Figs. 6A to 6C illustrate the total available sequence (SΕQ LD NO:3 and NO:4) of human MTHFR cDNA; Figs. 7A and 7B illustrate the expression analysis of MTHFR cDNA in E. Coli, respectively (7 A) the Western blot of bacterial extracts and tissues, and (7B) the thermolability assay of bacterial extracts; Figs. 8 A to 8D illustrate the identification of a 5' splice site mutation leading to a 57-bp in-frame deletion ofthe cDNA; Figs. 9A to 9D illustrate the diagnostic restriction endonuclease analysis of 4 mutations; Figs. 10A to 10D illustrate the ASO hybridization analysis of 2 mutations; Fig. 11 illustrates the region of homology between human methylenetetrahydrofolate reductase (MTHFR) and human dihydrofolate reductase (DHFR); Figs. 12A-12B illustrate the exonic sequences ofthe human MTHFR gene with their flanking intronic sequences; Figs. 13A-13B illustrate the exonic sequences ofthe mouse MTHFR gene with their flanking intronic sequences; Fig. 14 illustrates intron sizes and locations for both human and mouse genes; and Fig. 15 illustrates the alignment of MTHFR amino acid sequences for the human MTHFR (hMTHFR), mouse MTHFR (mMTHFR) and the MetF gene of bacteria (bMTHFR). DETAILED DESCRIPTION OF THE INVENTION Sequencing of peptides from porcine MTHFR Homogeneous native porcine MTHFR was digested with trypsin to generate a 40 kDa N-terminal fragment and a 31 kDa C-terminal fragment; the 31 kDa fragment is a proteolytic product ofthe 37 kDa fragment. The fragments were separated by SDS- PAGE, elecfroeluted, and the denatured fragments were digested with lysyl endopeptidase (LysC). The resulting peptides were separated by reversed-phase HPLC and subjected to sequence analysis by Edman degradation (details contained in Goyette P et al., Nature Genetics, 1994, 7:195-200). Isolation and sequencing of cDNAs Two degenerate oligonucleotides were synthesized based on the sequence of a 30 amino acid porcine MTHFR peptide (first underlined peptide in Fig. 2). These were used to generate a 90 bp PCR product, encoding the predicted peptide, from reverse tran- scription-PCR reactions of 500 ng pig liver ρolyA+ RNA. A pig-specific (non- degenerate, antisense) PCR primer was then synthesized from this short cDNA sequence. Using this primer and a primer for phage arms, a human liver λgtlO cDNA library (Clontech) was screened by PCR; this technique involved the generation of phage lysate stocks (50,000 pfu) which were boiled for 5 min and then used directly in PCR reactions with these two primers. PCR fragments were then sequenced directly (Cycle Sequencing ™ kit, GIBCO), and a positive clone was identified by comparison ofthe deduced amino acid sequence to the sequence ofthe pig peptide (allowing for inter-species variations). The positive stock was then replated at lower density and screened with the radiolabelled positive PCR product by plaque hybridization until a well-isolated plaque was identified. Phage DNA was purified and the insert was then subcloned into pBS+ (Bluescript) and sequenced on both strands (Cycle Sequencing™ kit, GIBCO and Sequenase™, Pharmacia). The deduced amino acid sequence ofthe human cDNA was aligned to the porcine peptide sequences, the rnetE genes from E. coli (ecomet accession number VO1502) and S. Typhimurium (stymetF, accession number XO7689) and with a previously unidentified open reading frame in Saccharomyces cerevisiae that is divergently transcribed with respect to the excision repair gene, ysRADl (accession number KO2070). The initial alignments were performed using BestFit™ in the GCG computer package, and these alignments were adjusted manually to maximize homologies. In summary, degenerate oligonucleotide primers were designed to amplify a sequence corresponding to a 30-amino acid segment of a porcine peptide from the N- terminal region ofthe enzyme (first porcine peptide in Fig. 2). A 90-bp porcine cDNA fragment was obtained from reverse transcription/PCR of pig liver RNA. Sequencing of the PCR fragment confirmed its identity by comparison ofthe deduced amino acid sequence to the porcine peptide sequence. A nondegenerate oligonucleotide primer, based on the internal sequence ofthe porcine cDNA, was used in conjunction with primers for the phage arms to screen a human liver λgtlO cDNA library by PCR. The insert ofthe positive clone was isolated and sequenced. The sequence consisted of 1266 bp with one continuous open reading frame. Homology with MTHFR in other species The deduced amino acid sequence ofthe human cDNA was aligned with the metE genes from E. coli and S. typhimurium, as well as with a previously unidentified ORF in Saccharomyces cerevisiae that is divergently transcribed with respect to the excision repair gene, ysRADl (Fig. 2). The sequences homologous to 5 porcine peptides are underlined in Fig. 2. Three segments (residues 61-94, 219-240, and 337-351) correspond to internal peptide sequence from the N-terminal 40-kDa domain ofthe porcine liver enzyme. Residues 374-393 correspond to the upstream portion ofthe LysC peptide from the C-terminal domain ofthe porcine liver enzyme that is labeled when the enzyme is irradiated with UN light in the presence of (3H-methyι)AdoMet; as predicted from the AdoMet labeling studies, this peptide lies at one end (Ν-terminal) ofthe 37 kDa domain. A fifth region of homology (residues 359-372) was also identified, but the localization ofthe porcine peptide within the native protein had not been previously determined. Methylenetetrahydrofolate reductase (MTHFR) is an enzyme involved in amino acid metabolism, that is critical for maintaining an adequate methionine pool, as well as for ensuring that the homocysteine concentration does not reach toxic levels. The high degree of sequence conservation, from E. coli to Homo sapiens, attests to the significance of MTHFR in these species. The enzyme in E. coli (encoded by the metE locus) is a 33-kDa peptide that binds reduced FAD and catalyzes the reduction of methylenetetrahydrofolate to methyltetrahydrofolate. The metE enzyme differs from the mammalian enzyme in that ΝADPH or ΝADH cannot reduce it, and its activity is not allosterically regulated by S-adenosylmethionine. The native porcine enzyme is susceptible to tryptic cleavage between the Ν-terminal 40 kDa domain and the C-terminal 37 kDa domain, and this cleavage results in the loss of allosteric regulation by adenosylmethionine, but does not result in loss of catalytic activity. Since the homology between the bacterial and mammalian enzymes is within the Ν-terminal domain, this region must contain the flavin binding site and residues necessary to bind the folate substrate and catalyze its reduction. The domain structure ofthe human enzyme has not been elucidated, although the human enzyme has been reported to have a molecular mass of 150 kDa and is likely to be a homodimer of 77 kDa. The predicted point of cleavage between the two domains lies between residues 351 and 374 ofthe human sequence, based on the localization of peptides obtained from the isolated domains ofthe porcine enzyme. This region, containing the highly charged sequence KRREED, is predicted to have the highest hydrophilicity and surface probability of any region in the deduced human sequence. The N-terminus ofthe porcine protein has been sequenced, and the region encoding this part ofthe protein is missing from the human cDNA. It is estimated that this cDNA is missing only a few residues at the N-terminus, since the predicted molecular mass ofthe deduced sequence upstream ofthe putative cleavage site (KRREED) is 40 kDa, and the measured molecular mass ofthe porcine N-terminal domain is also 40 kDa. When the bacterial, yeast and human sequences are aligned, the deduced human sequence contains an N-terminal extension of 40 amino acids; it is suspected that this extension contains determinants for NADPH binding. Many pyridine nucleotide-dependent oxidoreductases contain such determinants at the N-terminus ofthe protein. The C-terminus ofthe human sequence contains a peptide that is labeled when the protein is irradiated with ultraviolet light in the presence of tritiated AdoMet. The cDNA sequence reported here contains only about 7 kDa ofthe predicted 37-kDa mass of this domain, indicating that this cDNA is truncated at the 3' terminus as well. A number of peptides from the C-terminal porcine domain have also not been detected. As might be expected, given that the prokaryotic enzymes do not appear to be allosterically regulated by AdoMet, there are no significant homologies between the C-terminal region in this cDNA and the prokaryotic metE sequences. The alignment shown in Fig. 2 shows that the homologous sequences terminate just prior to the putative cleavage site ofthe human enzyme. Chromosomal assignment In situ hybridization to metaphase human chromosomes was used for localization ofthe human gene. The analysis ofthe distribution of 200 silver grains revealed a significant clustering of grain 40 grains, in the p36.3-36.2 region of chromosome 1 (pO.OOOl), with the majority of grains, 25 grains, observed over lp36.3. The isolation ofthe human cDNA has allowed us to localize the gene to chromosome lp36.3. The observation of one strong signal on that chromosome with little background is highly suggestive of a single locus with no pseudogenes. Southern blotting of human DNA revealed fragments of approximately 10 kb, predicting a gene of average size, since this cDNA encodes approximately half of the coding sequence. Additional cDNA sequences and constructs for expression analysis A human colon carcinoma cDNA library (gift of Dr. Nicole Beauchemin, McGill University) was screened by plaque hybridization with the original 1.3-kb cDNA to obtain additional coding sequences. A cDNA of 2.2 kb was isolated, which contained 1.3 kb of overlapping sequence to the original cDNA and 900 additional bp at the 3' end (Fig. 6). The amino acid sequence is identical to that ofthe original cDNA for the overlapping segment (codons 1-415) except for codon 177 (ASP) which was a GLY codon in the original cDNA. Analysis of 50 control chromosomes revealed an ASP codon at this position. The cDNA has an open reading frame of 1980 bp, 100 bp of 3' UTR and a poly A tail. Sequencing was performed on both strands for the entire cDNA. Additional 5' sequences (800 bp) were obtained from a human kidney cDNA library (Clontech) but these sequences did not contain additional coding sequences and were therefore used for the PCR-based mutagenesis only (as described below) and not for the expression analysis. The two cDNAs (2.2 kb and 800 bp) were ligated using the EcoRI site at bp 199 and inserted into the Bluescript™ vector (Stratagene). The 2.2 kb cDNA was subcloned into the expression vector pTrc99A (Pharmacia) using the Ncol site at bp 11 and the Xbal site in the polylihker region of both the Bluescript™ and the pTrc99A vectors. Sequencing was performed across the cloning sites to verify the wild-type construct. UTILITY OF INVENTION IN IDENTIFICATION OF MUTATIONS I. Identification of first two mutations in severe MTHFR deficiency Total RNA of skin fibroblasts from MTHFR-deficient patients was reverse- transcribed and amplified by PCR for analysis by the single strand conformation polymorphism (SSCP) method (Orita, M. et al, Genomics, 1989, 5:8874-8879). Primers were designed to generate fragments of 250-300 bp and to cover the available cDNA sequences with small regions of overlap for each fragment at both ends. The first mutation identified by SSCP was a C to T substitution at bp 559 in patient 1554; this substitution converted an arginine codon to a termination codon (Fig. 3 A). Since the mutation abolished a Fokl site, restriction digestion was used for confirmation ofthe change and for screening additional patients for this mutation; a second patient (1627) was identified in this manner (Fig. 3B). The SSCP pattern for patient 1554 and the restriction digestion pattern for both patients was consistent with a homozygous mutant state or with a genetic compound consisting ofthe nonsense mutation with a second mutation that did not produce any detectable RNA (null allele). Studies in the parents are required for confirmation. The second substitution (Fig. 4A) was a G to A transition at bp 482 in patient 1834 that converted an arginine into a glutamine residue. The substitution created a Pstl site that was used to verify the substitution and to identify a second patient (1863) with this change (Fig. 4B). The SSCP analysis and the restriction digestion pattern were consistent with a heterozygous state for both patients. The arginine codon affected by this change is an evolutionarily conserved residue, as shown in Fig. 2. This observation, in conjunction with the fact that the codon change is not conservative, makes a strong argument that the substitution is a pathologic change rather than a benign polymorphism. Furthermore, 35 controls (of similar ethnic background to that ofthe probands) were tested for this substitution by Southern blotting of PstJ-digested DNA; all were negative. The family of patient 1834 was studied. The symptomatic brother and the mother ofthe proband were all shown to carry this substitution, whereas the father was negative for the change (Fig. 4B). In the family of 1863, the mother ofthe proband was shown to be a carrier, while the father and an unaffected brother were negative. Cell lines Cell line 1554 is from a Hopi male who was admitted at age three months with homocystinuria, seizures, dehydration, corneal clouding, hypotonia and Candida sepsis. Folate distribution in cultured fibroblasts showed a Pediococcus cerivisiae/Lactobacillus casei (PC/LC) ratio of 0.52 (Control 0.14). There was no measurable methylenetetrahydrofolate reductase (MTHFR) activity (Control values = 9.7 and 15.1 nmoles/h/mg protein; residual activity after treatment of control extracts at 55°C for 20 min. = 28% and 31 %). Cell line 1627 is from a Choctaw male who presented with poor feeding, apnea, failure to thrive, dehydration and homocystinuria at five weeks of age. He was subsequently found to have superior sagittal sinus thrombosis and hydrocephalus. The PC/LC ratio was 0.61 and the specific activity of MTHFR was 0.1 nmoles/h/mg protein. There is consanguinity in that the maternal and paternal grandmothers are thought to be "distantly related". Cell line 1779 is from a French Canadian male with homocystinuria who first had limb weakness, uncoordination, paresthesiae, and memory lapses at age 15 years, and was wheelchair-bound in his early twenties. His brother (cell line 1834) also has homocystinuria, but is 37 years old and asymptomatic. Specific activity of MTHFR was 0.7 and 0.9 nmole/h/mg protein for 1779 and 1834, respectively; the residual activity after heat treatment at 55°C was 0.9% and 0% for 1779 and 1834, respectively. Cell line 1863 is from a white male who was diagnosed at age 21 years because of a progressive gait disturbance, spasticity, cerebral white matter degeneration, and homocystinuria. He had a brother who died at age 21 years of neurodegenerative disease. Specific activity of MTHFR in fibroblast extracts was 1.76 nmoles/h/mg protein and the residual enzyme activity after treatment at 55°C was 3.6%. Mutation analysis Primers were designed from the cDNA sequence to generate 250-300 bp fragments that overlapped 50-75 bp at each end. The primer pairs were used in reverse transcription-PCR of 5μg patient total fibroblast RNA. The PCR products were analyzed by a non-isotopic rapid SSCP protocol (PhastSystem™, Pharmacia), which uses direct silver staining for detection of single strands. Any PCR products from patients showing a shift on SSCP gels were purified by NuSieve (FMC Bioproducts) and sequenced directly (Cycle Sequencing™ kit, GIBCO) to identify the change. If the change affected a restriction site, then a PCR product was digested with the appropriate restriction endonuclease and analyzed on polyacrylamide gels. To screen for the Arg to Gin mutation in controls, 5 μg of PstJ-digested DNA was run on 0.8% agarose gels and analyzed by Southern blotting using the radiolabelled cDNA by standard techniques. II. Seven additional mutations at the methylenetetrahydrofolate reductase (MTHFR) locus with genotype: phenotype correlation in severe MTHFR deficiency It is reported hereinbelow the characterization of 7 additional mutations at this locus: 6 missense mutations and a 5' splice site defect which activates a cryptic splice site in the coding sequence. A preliminary analysis ofthe relationship between genotype and phenotype for all 9 mutations identified thus far at this locus is also reported. A nonsense mutation and 2 missense mutations (proline to leucine and threonine to methionine) in the homozygous state are associated with extremely low activity (0-3%) and onset of symptoms within the first year. Other missense mutations (arginine to cysteine and arginine to glutamine) are associated with higher enzyme activity and later onset of symptoms. 7 additional mutations at the MTHFR locus are described and the association between genotype, enzyme activity, and clinical phenotype in severe MTHFR deficiency is examined. Patient description The clinical and laboratory findings ofthe patients have been reported in the published literature. Residual MTHFR activity was previously measured in cultured fibroblasts at confluence. Patient 354, an African- American girl, was diagnosed at age 13 years with mild mental retardation. Her sister, patient 355 was diagnosed at age 15 years with anorexia, tremor, hallucinations and progressive withdrawal. In patient 354, residual MTHFR activity was 19% and in her sister, 355, it was 14% of control values. The residual activity after heating had equivalent thermal stability to control enzyme. Patient 1807, a Japanese girl whose parents are first cousins, had delayed walking and speech until age 2 years, seizures at age 6 years and a gait disturbance with peripheral neuropathy at age 16 years. Residual activity of MTHFR was 3% and the enzyme was thermolabile. Patient 735, an African-Indian girl, was diagnosed at age 7 months with microcephaly, progressive deterioration of mental development, apnea and coma. Residual activity of MTHFR was 2% of control levels. Thermal properties were not determined. Patient 1084, a Caucasian male, was diagnosed at age 3 months with an infantile fibrosarcoma. He was found to be hypotonic and became apneic. He died at the age of 4 months. Residual activity of MTHFR was not detectable. Thermal properties were not determined. Patient 356, the first patient reported with MTHFR deficiency, is an Italian- American male who presented at age 16 years with muscle weakness, abnormal gait and flinging movements ofthe upper extremities. MTHFR residual activity was 20% of control values; activity was rapidly and exponentially inactivated at 55°. Patient 458, a Caucasian male, was diagnosed at age 12 years with ataxia and marginal school performance. Residual MTHFR activity was approximately 10%, and the activity was thermolabile. Patient 1396, a Caucasian female, was described as clumsy and as having a global learning disorder in childhood. At age 14 years, she developed ataxia, foot drop, and inability to walk. She developed deep vein thrombosis and bilateral pulmonary emboli. Residual activity of MTHFR was 14% and the enzyme was thermolabile. Genomic structure and intronic primers Exon nomenclature is based on available cDNA sequence in Goyette et al. (Nature Genetics, 1994, 7:195-200). Exon 1 has been arbitrarily designated as the region of cDNA from bp 1 to the first intron. Identification of introns was performed by amplification of genomic DNA using cDNA primer sequences. PCR products that were greater in size than expected cDNA sizes were sequenced directly. Mutation detection Specific exons (see Table 1 for primer sequences) were amplified by PCR from genomic DNA and analyzed by the SSCP protocol. SSCP was performed with the Phastgel™ system (Pharmacia), a non-isotopic rapid SSCP protocol, as previously described (Goyette P et al., Nature Genetics, 1994, 7:195-200), or with 35 S-labeled PCR products run on 6% acrylamide: 10% glycerol gels at room temperature (6 watts, overnight). In some cases, the use of restriction endonucleases, to cleave the PCR product before SSCP analysis, enhanced the detection of band shifts. PCR fragments with altered mobility were sequenced directly (GIBCO, Cycle Sequencing™ kit). If the sequence change affected a restriction endonuclease site, then the PCR product was digested with the appropriate enzyme and analyzed by PAGE. Otherwise, allele-specific oligonucleotide (ASO) hybridization was performed on a dot blot ofthe PCR-amplified exon. Table 1 PCR Primers for DΝA amplification and mutation analysis of MTHFR Exon Primer Primer Sequence (5'→3') Location Fragment Size Type (bp) 1 Sense AGCCTCAACCCCTGCTTGGAGG (SEQ ID ΝO:5) C 271 Antisense TGACAGTTTGCTCCCCAGGCAC (SEQ ID NO:6) I 4 Sense TGAAGGAGAAGGTGTCTGCGGGA (SEQ ID NO:7) c 198 Antisense AGGACGGTGCGGTGAGAGTGG (SEQ ID NO:8) I 5 Sense CACTGTGGTTGGCATGGATGATG (SEQ ID NO:9) I 392 Antisense GGCTGCTCTTGGACCCTCCTC (SEQ ID NO: 10) I 6 Sense TGCTTCCGGCTCCCTCTAGCC (SEQ ID NO: 11) I 251 Antisense CCTCCCGCTCCCAAGAACAAAG (SEQ ID NO: 12) I Table 2 Summary of genotypes, enzyme activity, age at onset, and background of patients with MTHFR deficiency Patient a BPChanges b Amino acid % Age at Onset Background changes Activity 1807 C764T/C764T Pro→Leu/Pro→Leu 3 within 1st year Japanese 735 C692T/C692T Thr→Met/Thr→Met 2 7 months African Indian 1084 C692T/C692T Thr→Met/Thr→Met 0 3 months Caucasian 1554 C559T/C559T Arg→Ter/Arg→Ter 0 1 month Native American (Hop.) 1627 C559T/C559T Arg→Ter/Arg→Ter 1 1 month Native American (Choctaw) 356 C985T/C985T Arg→Cys/Arg→ 20 16 yrs Italian American Cys 458 C1015T/G167A Arg→Cys/Arg→ 10 11 yrs Caucasian Gin 1396 C1081T/G167A Arg→Cys/Arg→ 14 14 yrs Caucasian Gin 1779 c G482A/? Arg→Gln/? 6 15 yrs French Canadian 1834 c G482A/? Arg→Gln/? 7 Asymptomatic French Canadian at 37 yrs 1863 G482A/? Arg→Gln/? 14 21 yrs Caucasian 354 d 792 + lG→A/? 5' splice site/? 19 13 yrs African American 355 d 792 + lG→A/? 5 1 splice site/? 14 11 yrs African American a Patients 1554, 1627, 1779, 1834 and 1863 were previously reported by Goyette et al. (1994). ? = unidentified mutation. c Patients 1779 and 1834 are sibs. Patients 354 and 355 are sibs. (1) 5' splice site mutation Amplification of cDNA, bp 653-939, from reverse-transcribed total fibroblast RNA revealed 2 bands in sisters 354 and 355: a smaller PCR fragment (230 bp) in addition to the normal 287 bp allele (Fig. 8A). Fig. 8A is the PAGE analysis of amplification products of cDNA bp 653-939, from reverse transcribed RNA. Controls have the expected 287-bp fragment while patients 354 and 355 have an additional 230-bp fragment. Sequencing ofthe smaller fragment identified a 57-bp in-frame deletion which would remove 19 amino acids (Fig. 8B). Fig. 8B is the direct sequencing ofthe PCR products from patient 354. The 57-bp deletion spans bp 736-792 ofthe cDNA. An almost perfect 5' splice site (boxed) is seen at the 5' deletion breakpoint. Analysis ofthe sequence at the 5' deletion breakpoint in the undeleted fragment revealed an almost perfect 5' splice site consensus sequence (AG/gcatgc). This observation suggested the presence of a splicing mutation in the natural 5' splice site that might activate this cryptic site, to generate the deleted allele. The sequence following the deletion breakpoint, in the mutant allele, corresponded exactly to the sequence ofthe next exon. Amplification of genomic DNA, using the same amplification primers as those used for reverse-transcribed RNA, generated a 1.2-kb PCR product indicating the presence of an intron. Direct sequencing of this PCR fragment in patient 354 identified a heterozygous G-→-A substitution in the conserved GT dinucleotide ofthe intron at the 5' splice site (Fig. 8C). Fig. 8C is the sequencing ofthe 5' splice site in control and patient 354. The patient carries a heterozygous G-→A substitution in the 5' splice site (boxed). Intronic sequences are in lower case. This substitution abolished a Hphl restriction endonuclease site which was used to confirm the mutation in the 2 sisters (Fig. 8D). Fig. 8D is the Hphl restriction endonuclease analysis on PCR products of DNA for exon 4 of patients 354 and 355, and of 3 controls (C). The 198-bρ PCR product has 2 Hphl sites. The products of digestion for the control allele are 151, 24 and 23 bp. The products of digestion for the mutant allele are 175 and 23 bp due to the loss of a Hphl site. The fragments of 24 and 23 bp have been run off the gel. (2) Patients with homozygous coding substitutions SSCP analysis of exon 4 for patient 1807 revealed an abnormally-migrating fragment, which was directly sequenced to reveal a homozygous C— »T substitution (bp 764) converting a proline to a leucine residue. This change creates a MnR. restriction endonuclease site, which was used to confirm the homozygous state ofthe mutation (Fig. 9A). Fig. 9A is the MnK restriction analysis of exon 4 PCR products for patient 1807 and 3 controls (C). Expected fragments: control allele, 90, 46, 44, 18 bp; mutant allele, 73, 46, 44, 18, 17 bp. An additional band at the bottom ofthe gel is the primer. Fifty independent control Caucasian chromosomes and 12 control Japanese chromosomes were tested by restriction analysis; all were negative for this mutation. Homozygosity in this patient is probably due to the consanguinity ofthe parents. Patients 735 and 1084 had the same mutation in exon 4, in a homozygous state: a C-»T substitution (bp 692) which converted an evolutionarily conserved threonine residue to a methionine residue, and abolished a Nlalϊl restriction endonuclease site. Allele-specific oligonucleotide hybridization to amplified exon 4 (Figs. 10A and 10B) was used to confirm the mutation in these 2 patients and to screen 60 independent chromosomes, all of which turned out to be negative. Fig. 10A is the hybridization of mutant oligonucleotide (692T) to exon 4 PCR products from patients 735, 1084 and 30 controls. Only DNA from patients 735 and 1084 hybridized to this probe. Fig. 10B is the hybridization of normal oligonucleotide (692C) to stripped dot blot from A. All control DNAs hybridized to this probe. Patient 356 showed a shift on SSCP analysis of exon 5. Direct sequencing revealed a homozygous C-»T substitution (bp 985) which converted an evolutionarily conserved arginine residue to cysteine; the substitution abolished an Acil restriction endonuclease site. This was used to confirm the homozygous state ofthe mutation in patient 356 (Fig. 9B) and its presence in the heterozygous state in both parents. Fifty independent control chromosomes, tested in the same manner, were negative for this mutation. Fig. 9B is the Acil restriction analysis of exon 5 PCR products for patient 356, his father (F), his mother (M), and 3 controls (C). Expected fragments: control allele, 129, 105, 90, 68 bp; mutant allele, 195, 129, 68 bp. (3) Patients who are genetic compounds Patient 458 is a compound heterozygote of a mutation in exon 5 and a mutation in exon 1. The exon 5 substitution (C-»T at bp 1015) resulted in the substitution of a cysteine residue for an arginine residue; this abolished a Hhal restriction endonuclease site, which was used to confirm the mutation in patient 458 (Fig. 9C) and to show that 50 control chromosomes were negative. Fig. 9C is the Hb l restriction analysis of exon 5 PCR products for patient 458 and 4 controls (C). Expected fragments: control allele, 317 and 75 bp; mutant allele 392 bp. The 75-bp fragment is not shown in Fig. 9C. The second mutation was a heterozygous G-»A substitution (bp 167) converting an arginine to a glutamine residue. Allele-specific oligonucleotide hybridization to amplified exon 1 confirmed the heterozygous state of this mutation in patient 458 and identified a second patient (1396) carrying this mutation also in the heterozygous state (Figs. IOC and 10D). Fig. IOC is the hybridization of mutant oligonucleotide (167 A) to exon 1 PCR products from patients 458, 1396 and 31 controls. Fig. 10D is the hybridization of normal oligonucleotide (167G) to stripped dot blot from C. None ofthe 62 control chromosomes carried this mutation. The second mutation in patient 1396 was identified in exon 6: a heterozygous C— »T substitution (bp 1081) that converted an arginine residue to a cysteine residue, and abolished a Hhal restriction endonuclease site. Restriction analysis confirmed the heterozygous substitution in 1396 (Fig. 9D) and showed that 50 control chromosomes were negative. Tooth decay does not occur in patients having a saliva above pH 5.0. Fig. 9D is the Hhal restriction analysis of exon 6 PCR products for patient 1396 and 2 controls (C). Expected fragments: control allele, 152, 86, 13 bp; mutant allele 165, 86 bp. The 13 -bp fragment has been run off the gel. (4) Additional sequence changes Hhal analysis of exon 6, mentioned above, revealed a DNA polymorphism. This change is a T-»C substitution at bp 1068 which does not alter the amino acid (serine), but creates a Hhal recognition site. T at bp 1068 was found in 9% of tested chromosomes. Sequence analysis identified 2 discrepancies with the published cDNA sequence: a G→A substitution at bp 542 which converts the glycine to an aspartate codon, and a C— »T change at bp 1032 which does not alter the amino acid (threonine). Since all DNAs tested (>50 chromosomes) carried the A at bp 542 and the T at bp 1032, it is likely that the sequence ofthe original cDNA contained some cloning artifacts. Genotype.phenotype correlation Table 2 summarizes the current status of mutations in severe MTHFR deficiency. In 8 patients, both mutations have been identified; in 5 patients (3 families), only 1 mutation has been identified. Overall the correlation between the genotype, enzyme activity, and phenotype is quite consistent. Five patients, with onset of symptoms within the first year of life, had < 3% of control activity. Three of these patients had missense mutations in the homozygous state: two patients with the threonine to methionine substitution (C692T) and one patient with the proline to leucine substitution (C764T). The nonsense mutation (C559T) in the homozygous state in patients 1554 and 1627 (previously reported in Goyette P et al., Nature Genetics, 199 A, 7:195-200) is also associated with a neonatal severe form, as expected. The other patients in Table 2 had > 6% of control activity and onset of symptoms within or after the 2nd decade of life; the only exception is patient 1834, as previously reported (Goyette P et al, Nature Genetics, 1994, 7:195-200). The three patients (356, 458 and 1396) with missense mutations (G167A, C985T, C1015T and C 108 IT) are similar to those previously reported (patients 1779, 1834 and 1863) who had an arginine to glutamine substitution and a second unidentified mutation (Goyette P et al., Nature Genetics, 1994, 7:195-200). The sisters with the 5' splice mutation and an unidentified second mutation also had levels of activity in the same range and onset of symptoms in the second decade, but the activity is likely due to the second unidentified allele. Discussion The patients come from diverse ethnic backgrounds. Although patients 1554 and 1627 are both Native Americans, the mutations occur on different haplotypes, suggesting recurrent mutation rather than identity by descent. Since the substitution occurs in a CpG dinucleotide, a "hot spot" for mutation, recurrent mutation is a reasonable hypothesis. It is difficult to assess whether some mutations are population- specific since the numbers are too small at the present time. MTHFR deficiency is the most common inborn error of folate metabolism, and a major cause of hereditary homocysteinemia. The recent isolation of a cDNA for MTHFR has permitted mutational analysis at this locus, with the aims of defining important domains for the enzyme and of correlating genotype with phenotype in MTHFR-deficient patients. The 7 mutations described here (6 single amino acid substitutions and a 5' splice site mutation) bring the total to 9 mutations identified thus far in severe MTHFR deficiency and complete the mutation analysis for 8 patients. The identification of each mutation in only one or two families points to the striking degree of genetic heterogeneity at this locus. Seven ofthe 9 mutations are located in CpG dinucleotides, which are prone to mutational events. 5' splice site mutation The G— »A substitution at the GT dinucleotide ofthe 5' splice site in patients 354 and 355 results in a 57bp in-frame deletion ofthe coding sequence, which should delete 19 amino acids ofthe protein. This deletion occurs as a result ofthe activation of a cryptic 5' splice site (AG/gc) even though this cryptic site does not have a perfect 5' splice site consensus sequence (AG/gt). However, GC (instead of GT) as the first 2 nucleotides of an intron has been reported in several naturally-occurring splice sites, such as in the genes for human prothrombin and human adenine phosphoribosyltransferase and twice within the gene for the largest subunit of mouse RNA polymerase II. The remaining nucleotides ofthe cryptic site conform to a normal splice site consensus sequence with its expected variations (Ago G79/gl00^100 a 59 a 71S82^5θ)- ^ ^ s unlikely that the deleted enzyme resulting from this aberrantly-spliced mRNA would have any activity; 8 ofthe 19 deleted amino acids are conserved in the E. Coli enzyme. Although the 2 patients show residual enzyme activity in the range of 20% of controls, the activity is probably due to the unidentified second allele in these patients. 6 missense mutations The Arg— »Cys substitution (C1081T) in patient 1396 is within a hydrophilic sequence previously postulated to be the linker region between the catalytic and regulatory domains of MTHFR (Goyette P et al, Nature Genetics, 1994, 7:195-200). These 2 domains are readily separable by mild trypsinization ofthe porcine enzyme. The linker domain, a highly-charged region, is likely to be located on the outside surface of the protein and therefore more accessible to proteolysis. Because the Arg-»Cys substitution converts a charged hydrophilic residue to an uncharged polar residue, it cannot be considered a conservative change, and could affect the stability ofthe enzyme. The 2 Arg→Cys substitutions identified in patients 356 and 458 (C985T and C1015T, respectively) may be involved in binding the FAD cofactor. Previous work in the literature showed that heating fibroblast extracts at 55°, in the absence ofthe FAD cofactor, inactivated MTHFR completely. The addition of FAD to the reaction mixture before heat inactivation restored some enzyme activity to control extracts and to extracts from some patients, while the extracts of patients 356 and 458 were unaffected. Based on these observations, it was suggested that these 2 patients had mutations affecting a region ofthe protein involved in binding FAD. The 2 mutations are found in close proximity to each other, within 11 amino acids. In patient 356, the Arg residue is evolutionarily- conserved in E. Coli and is found in a stretch of 9 conserved amino acids, suggesting a critical role for this residue; the altered Arg residue in patient 458 is not evolutionarily- conserved. Crystal structure analysis of medium chain acyl-CoA dehydrogenase (MCAD), a flavoprotein, has defined critical residues involved in the binding of FAD. Two consecutive residues ofthe MCAD protein, Met 165 and Tip 166, involved in interactions with FAD, can also be identified in MTHFR, 3 and 4 amino acids downstream, respectively, from the Arg residue altered in patient 458. The Thr— »Met substitution (C692T) is found in a region of high conservation with the E. Coli enzyme and in a region of good homology with human dihydrofolate reductase (DHFR) (Fig. 11). In Fig. 11, = is identity; • is homology; and $ is identity to bovine DHFR enzyme. An asterisk (*) indicates location of Thr→Met substitution. Considering the early-onset phenotype ofthe patients, one can assume that the threonine residue is critical for activity or that it contributes to an important domain ofthe protein. This region of homology in DHFR contains a residue, Thr 136, which has been reported to be involved in folate binding. This Thr residue in DHFR aligns with a Ser residue in MTHFR, an amino acid with similar biochemical properties. The Thr — » Met substitution is located 8 amino acids downstream from this Ser codon, in the center ofthe region of homology between the 2 enzymes. It is therefore hypothesized that the Thr -» Met substitution may alter the binding ofthe folate substrate. The G167A (Arg → Gin) and C764T (Pro → Leu) substitutions both affect non-conserved amino acids. Their importance in the development of MTHFR deficiency cannot be determined at the present time. All the mutations identified thus far are located in the 5' end ofthe coding sequence, the region thought to encode the catalytic domain of MTHFR. Mutation analysis has been useful in beginning to address the structure: function properties ofthe enzyme as well as to understand the diverse phenotypes in severe MTHFR deficiency. III. Identification of A-XV mutation SSCP analysis and direct sequencing of PCR fragments were used to identify a C to T substitution at bp 677, which converts an alanine residue to a valine residue (Fig. 5 A). The primers for analysis ofthe A→V change are: 5'-TGAAGGAGAA GGTGTCTGCG GGA-3' (SEQ ID NO: 13) (exonic) and 5*-AGGACGGTGC GGTGAGAGTG-3' (SEQ ID NO: 14) (intronic); these primers generate a fragment of 198 bp. Fig. 5 A depicts the sequence of two individuals, a homozygote for the alanine residue and a homozygote for the valine residue. The antisense strands are depicted. This alteration creates a Hinfl site (Fig. 5B), which was used to screen 114 unselected French Canadian chromosomes; the allele frequency ofthe substitution was .38. The substitution creates a Hinfl recognition sequence which digests the 198 bp fragment into a 175 bp and a 23 bp fragment; the latter fragment has been run off the gel. Fig. 5B depicts the three possible genotypes. The frequency ofthe 3 genotypes were as follows: -/-, 37%; +/-, 51%; and +/+, 12% (the (+) indicates the presence ofthe Hinfl restriction site and a valine residue). The alanine residue is conserved in porcine MTHFR, as well as in the corresponding etF and stymetF genes of E. Coli and S. Typhimurium, respectively. The strong degree of conservation of this residue, and its location in a region of high homology with the bacterial enzymes, alluded to its importance in enzyme structure or function. Furthermore, the frequency ofthe (+/+) genotype was consistent with the frequency ofthe thermolabile MTHFR variant implicated in vascular disease. Clinical material To determine the frequency ofthe A-»N mutation, DΝA from 57 individuals from Quebec was analyzed by PCR and restriction digestion. The individuals, who were all French Canadian, were not examined clinically or biochemically. The 40 individuals analyzed in Table 3 had been previously described in Engbersen et al. (Am. J. Hum. Genet, 1995, 56:142-150). Ofthe 13 cardiovascular patients, 8 had cerebrovascular arteriosclerosis and 5 had peripheral arteriosclerosis. Five had thermolabile MTHFR while 8 had thermostable MTHFR (greater than 33% residual activity after heating). Controls and patients were all Dutch-Caucasian, between 20-60 years of age. None of these individuals used vitamins which could alter homocysteine levels. Enzyme assays and homocysteine determinations were also reported by Engbersen et al. (Am. J. Hum. Genet., 1995, 56:142-150). Table 3 Correlation between MTHFR genotype and enzyme activity, thermolability and plasma homocysteine level -/- +/- +/+ n=19 n=9 n=12 specific activity 3 '" 22.9± 1.7 15.0 ± 0.8 6.9 ± 0.6 (nmol CH2θ/mg.protein/hr) (11.8 - 33.8) (10.2-18.8) (2.6-10.2) residual activity after heating 3 '*' (%) 66.8 ± 1.5 56.2 ± 2.8 21.8 ± 2.8 (55-76) (41-67) (10-35) plasma homocysteine a > c 12.6 ± 1.1 13.8 ± 1.0 22.4 ± 2.9 (μM)(after fasting) (7-21) (9.6-20) (9.6-42) plasma homocysteine a ' c 41.3 ± 5.0 d 41 ± 2.8 72.6 ± 11.7 e (μM)(post-methionine load) (20.9 -110) (29.1-54) (24.4-159) a one-way anova p<.01 paired t test for all combinations p<.01 0 paired t test p<.05 for +/+ group versus +/- group or -/- group; p>.05 for +/- versus -/- group. n=l 8 for this parameter e n=l 1 for this parameter Enzyme activity and plasma homocysteine were determined as previously reported. Each value represents mean ± standard error. The range is given in parentheses below the mean. Correlation of A- V mutation with altered MTHFR function A genotypic analysis was performed and enzyme activity and thermolability were measured in a total of 40 lymphocyte pellets from patients with premature vascular disease and controls. 13 vascular patients were selected from a previous study (Engbersen et al., Am. J. Hum. Genet., 1995, 56:142-150), among which 5 were considered to have thermolabile MTHFR. From a large reference group of 89 controls, all 7 individuals who had thermolabile MTHFR were studied, and an additional 20 controls with normal MTHFR were selected from the same reference group. Table 3 documents the relationship between genotypes and specific enzyme activity, thermolability and plasma homocysteine level. The mean MTHFR activity for individuals homozygous for the substitution (+/+) was approximately 30% ofthe mean activity for (-/-) individuals, homozygous for the alanine residue. Heterozygotes had a mean MTHFR activity that was 65% ofthe activity of (-/-) individuals; this value is intermediate between the values for (-/-) and (+/+) individuals. The ranges of activities showed some overlap for the heterozygous and (-/-) genotypes, but homozygous (+/+) individuals showed virtually no overlap with the former groups. A one-way analysis of variance yielded a p value <.0001; a pairwise Bonferroni t test showed that all three genotypes were significantly different with p<0.01 for the three possible combinations. The three genotypes were all significantly different (p<.01) with respect to enzyme thermolability. The mean residual activity after heat inactivation for 5 minutes at 46° was 67%o, 56% and 22% for the (-/-), (+/-) and (+/+) genotypes, respectively. While the degree of thermolability overlaps somewhat for (-/-) individuals and heterozygotes, individuals with two mutant alleles had a distinctly lower range. Every individual with the (+/+) genotype had residual activity <35% after heating, and specific activity <50% of that ofthe (-/-) genotype. Total homocysteine concentrations, after fasting and 6 hours after methionine loading, were measured in plasma by high performance liquid chromatography using fluorescence detection. Fasting homocysteine levels in (+/+) individuals were almost twice the value for (+/-) and (-/-) individuals. The differences among genotypes for plasma homocysteine were maintained when homocysteine was measured following 6 hours of methionine loading. A one-way anova yielded a p < .01 for the fasting and post- methionine homocysteine levels. A pairwise Bonferroni t test showed that only homozygous mutant individuals had significantly elevated homocysteine levels (p<.05). PCR-based mutagenesis for expression of A-XV mutation in vitro PCR-based mutagenesis, using the cDNA-containing Bluescript™ vector as template, was used to create the A to V mutation. Vent™ polymerase (NEB) was used to reduce PCR errors. The following primers were used: primer 1, bp -200 to -178, sense; primer 2, bp 667 to 687, antisense, containing a mismatch, A, at bp 677; primer 3, 667 to 687, sense, containing a mismatch, T, at bp 677; primer 4, bp 1092 to 1114, antisense. PCR was performed using primers 1 and 2 to generate a product of 887 bp, and using primers 3 and 4 to generate a product of 447 bp. The two PCR fragments were isolated from a 1.2% agarose gel by Geneclean™ (BIO 101). A final PCR reaction, using primers 1 and 4 and the first 2 PCR fragments as template, was performed to generate a 1.3 kb band containing the mutation. The 1.3 kb fragment was digested with Ncol and Mscl, and inserted into the wild-type cDNA- containing expression vector by replacing the sequences between the Ncol site at bp 11 and the Mscl site at bp 943. The entire replacement fragment and the cloning sites were sequenced to verify that no additional changes were introduced by PCR. Expression analysis of wild-type and mutagenized cDΝA Overnight cultures of JM105™ containing vector alone, vector + wild-type MTHFR cDΝA, or vector + mutagenized cDΝA were grown at 37° C. in 2 x YT media with .05 mg/ml ampicillin. Fresh 10 ml. cultures of each were inoculated with approximately 50 μL of overnight cultures for a starting O.D. of 0.05, and were grown at 37° C to an O.D. of 1 at 420 nM. Cultures were then induced for 2 hrs. with 1 mM IPTG and pelleted. The cells were resuspended in TE buffer with 2 μg/ml aprotinin and 2μg/ml leupeptin (3.5 x wet weight of cells). Cell suspensions were sonicated on ice for 3 x 15 sec. to break open cell membranes and then centrifuged for 30 min. at 4°C. to pellet cell debris and unlysed cells. The supernatant was removed and assayed for protein concentration with the Bio-Rad™ protein assay. Western analysis was performed using the Amersham ECL™ kit according to the instructions ofthe supplier, using antiserum generated against purified porcine liver MTHFR. Enzymatic assays were performed by established procedures; pre-treating the extracts at 46°C. for 5 min. before determining activity assessed thermolability. Specific activities (nmol formaldehyde/hr./rng. protein) were calculated for the 2 cDΝA-containing constructs after subtraction ofthe values obtained with vector alone (to subtract background E. Coli MTHFR activity). The MTHFR cDΝA (2.2 kb) (Fig. 6) has an open reading frame of 1980 bp, predicting a protein of 74.6 kDa. The purified porcine liver enzyme has been shown to have subunits of 77 kDa. Western analysis (Fig. 7A) of several human tissues and of porcine liver has revealed a polypeptide of 77 kDa in all the studied tissues, as well as an additional polypeptide of approximately 70 kDa in human fetal liver and in porcine liver, suggesting the presence of isozymes. Two μg of bacterial extract protein was used for lanes 1-3. The tissues (lanes 4-8) were prepared by homogenization in .25M sucrose with protease inhibitors (2 μg/ml each of aprotinin and leupeptin), followed by sonication (3 x 15 sec.) on ice. The extracts were spun for 15 min. in a microcentrifuge at 14,000 g and 100 μg of supernatant protein was used for Western analysis. h=human; p=porcine. The wild-type cDNA and a mutagenized cDNA, containing the A— »N substitution, were expressed in E. Coli to yield a protein of approximately 70 kDa (Fig. 7 A), which co-migrates with the smaller polypeptide mentioned above. Treatment of extracts at 46°C for 5 minutes revealed that the enzyme containing the substitution was significantly more thermolabile than the wild-type enzyme (p<.001; Fig. 7B). Two separate experiments (with 3-4 replicates for each construct for each experiment) were performed to measure thermostable activity ofthe wild-type MTHFR and mutagenized MTHFR A-»N cDΝAs. The values shown represent mean ± standard error for each experiment, as % of residual activity after heating. The means ofthe specific activities before heating (expressed as nmol formaldehyde/hr./mg. protein) were as follows: Εxp. 1, 3.8 and 5.3 for MTHFR and MTHFR A→V, respectively; Εxp. 2, 6.2 and 7.5 for MTHFR and MTHFR A→V, respectively. The expression experiments were not designed to measure differences in specific activity before heating, since variation in efficiencies of expression could contribute to difficulties in interpretation. Curiously though, the specific activity for the mutant construct was higher in both experiments. It is possible that the mutant protein has increased stability in E. Coli, or that inclusion bodies in the extracts contributed to differences in recovery of properly-assembled enzyme. These studies have identified a common substitution in the MTHFR gene which results in thermolability in vitro and in vivo. The mutation, in the heterozygous or homozygous state, correlates with reduced enzyme activity and increased thermolability of MTHFR in lymphocyte extracts. A significant elevation in plasma homocysteine was observed in individuals who were homozygous for the mutation. Statistically-significant differences for homocysteine levels were not observed between heterozygotes and (-/-) individuals; this observation is not surprising, since plasma homocysteine can be influenced by several environmental factors, including intake of folate, vitamin Bi2 > vitamin Bg, and methionine, as well as by genetic variation at other loci, such as the cystathionine-β-synthase gene. The alanine to valine substitution conserves the hydrophobicity ofthe residue and is associated with small changes in activity, in contrast to non-conservative changes, such as the previously-reported arginine to glutamine change in MTHFR, which is associated with a greater decrease in enzyme activity and severe hyperhomocysteinemia. The alanine residue is situated in a region of homology with the bacterial metF genes. The same region of homology was also observed in the human dihydrofolate reductase (DHFR) gene (Fig. 11), although the alanine residue itself is not conserved; this region of amino acids 130-149 of DHFR contains T136 which has been implicated in folate binding in an analysis ofthe crystal structure of recombinant human DHFR. It is tempting to speculate that this region in MTHFR is also involved in folate binding and that the enzyme may be stabilized in the presence of folate. This hypothesis is compatible with the well-documented influence of folate on homocysteine levels and with the reported correction of mild hyperhomocysteinemia by folic acid in individuals with premature vascular disease, and in individuals with thermolabile MTHFR. Although the cDNA is not long enough to encode the larger MTHFR polypeptide, it is capable of directing synthesis ofthe smaller isozyme. The ATG start codon for this polypeptide is within a good consensus sequence for translation initiation. Whether the isozyme is restricted to liver and what its role is in this tissue remain to be determined. These data have identified a common genetic change in MTHFR which results in thermolability; these experiments do not directly address the relationship between this change and vascular disease. Nonetheless, this polymorphism represents a diagnostic test for evaluation of MTHFR thermolability in hyperhomocysteinemia. Large case-control studies are required to evaluate the frequency of this genetic change in various foi s of occlusive arterial disease and to examine the interaction between this genetic marker and dietary factors. Well-defined populations need to be examined, since the limited data set thus far suggests that population-specific allele frequencies may exist. More importantly, however, the identification of a candidate genetic risk factor for vascular disease, which may be influenced by nutrient intake, represents a critical step in the design of appropriate therapies for the homocysteinemic form of arteriosclerosis. cDNA FOR MTHFR AND ITS POTENTIAL UTILITY The cDNA sequence is a necessary starting point for the detection of MTHFR sequence abnormalities that would identify individuals at risk for cardiovascular and neurological diseases, as well as other disorders affected by folic acid metabolism. Diagnostic tests by DNA analysis are more efficient and accurate than testing by enzymatic/biochemical assays. Less blood is required and results are available in a shorter period of time. The tests could be performed as a routine operation in any laboratory that performs molecular genetic diagnosis, without the specialized reagents/expertise that is required for an enzyme-based test. The second major utility ofthe cDNA would be in the design of therapeutic protocols, for correction of MTHFR deficiency. These protocols could directly involve the gene, as in gene therapy trials or in the use of reagents that could modify gene expression. Alternatively, the therapy might require knowledge ofthe amino acid sequence (derived from the cDNA sequence), as in the use of reagents that would modify enzyme activity. The identification of sequences and/or sequence changes in specific regions ofthe cDNA or protein, such as FAD binding sites or folate-binding sites, are useful in designing therapeutic protocols involving the above nutrients. UTILITY OF INVENTION IN CLINICAL AND DIAGNOSTIC STUDIES Coronary artery disease patients in Montreal (n=153) were studied to examine the frequency ofthe alanine to valine substitution. Fourteen percent ofthe patients were homozygous for this mutation. An analysis of 70 control individuals (free of cardiovascular disease) demonstrated that only seven % of these individuals were homozygous for the alanine to valine mutation. Analysis of homocysteine levels in 123 men ofthe above patient group indicated that the mutant allele significantly raised homocysteine levels from 10.2 micromoles/L in homozygous normal men to 11.5 and 12.7 in heterozygotes and homozygous mutants, respectively. Families with a child with spina bifida, a neural tube defect, have been examined for the presence ofthe alanine to valine mutation. Approximately 16% of mothers who had a child with spina bifida were homozygous for this mutation, while only 5% of control individuals were homozygous. Fathers of children with spina bifida also had an increased prevalence ofthe homozygous mutant genotype (10%) as did the affected children themselves (13%). Table 4 indicates the interactive effect of folic acid with the homozygous mutant alanine to valine change. In a study of families from Framingham, Massachusetts and Utah, individuals who were homozygous mutant but had folate levels above 5 ng/ml did not have increased homocysteine levels compared to individuals with the normal or heterozygous genotype. However, individuals who were homozygous mutant but had folate levels below 5 ng/ml had homocysteine levels that were significantly higher than the other genotypes. Table 4 Mean fasting and PML homocysteine levels for different MTHFR genotypes MTHFR genotype Plasma Homocysteine Normals (-/-) Heterozygotes (+/-) Homozygotes (+/+) ^trend N 58 61 30 Fasting* 9.4 9.2 12.1 0.02 Folate <5 ng/mL 10.2 10.4 15.2 0.002 Folate 3 5ng/mL 8.2 7.5 7.5 0.52 Post-Methionine load 30.0 30.9 31.3 0.62 * Significant interaction between folate levels and genotype (p=0.03) Table 4 provides preliminary data for therapeutic intervention by folic acid supplementation to individuals who are homozygous for the alanine to valine change. The data suggest that higher levels of plasma folate would lead to normalization of homocysteine levels in mutant individuals and might prevent the occurrence of disorders associated with high homocysteine levels, such as cardiovascular disease, neural tube defects, and possibly other disorders. Folic acid supplementation for mutant individuals might also restore methionine and S-adenosylmethionine levels to normal. This would be relevant for disorders that are influenced by methylation, such as neoplasias, developmental anomalies, neurologic disease, etc. Genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased activity A common mutation (C677T) results in a thermolabile enzyme with reduced specific activity (approximately 35% of control values in homozygous mutant individuals). Homozygous mutant individuals (approximately 10% of North Americans) are predisposed to mild hyperhomocysteinemia, when their folate status is low. This genetic-nutrient interactive effect is believed to increase the risk for neural tube defects (NTD) and vascular disease. There has been reported an increased risk for spina bifida in children with the homozygous 1 mutant genotype for C677T. With the present invention, a second common variant in MTHFR (A1298C), an E to A substitution has been characterized. Homozygosity was observed in approximately 10% of Canadian individuals. This polymorphism was associated with decreased enzyme activity; homozygotes had approximately 60% of control activity in lymphocytes. A sequence change (C 1298 A) has been identified. Heterozygotes for both the C677T and the A1298C mutation, approximately 15% of individuals, had 50%-60% of control activity, a value that was lower than that seen in single heterozygotes for the C677T variant. No individuals were homozygous for both mutations. A silent genetic variant T1317C, was identified in the same exon. It was relatively infrequent (allele frequency = 5%) in the study group, but was common in a small sample of African individuals (allele frequency = 39%). In addition, by virtue of the role of MTHFR in folate-dependent homocysteine metabolism, the C677T mutation predisposes to mild hyperhomocysteinemia, a risk factor for vascular disease, in the presence of low folate status. By the present invention, the frequency ofthe A1298C variant has been determined and its potential impact on enzyme function has been assessed. Patients with spina bifida and mothers of patients were recruited from the Spina Bifida Clinic at the Montreal Children's Hospital following approval from the Institutional Review Board. Control children and mothers of controls were recruited from the same institution. Blood samples were used to prepare DNA from peripheral leukocytes, to assay MTHFR activity in lymphocyte extracts, and to measure total plasma homocysteine (tHcy). The presence ofthe C677T mutation (A to N) was evaluated by PCR and Hinfl digestion (2). The A1298C mutation was initially examined by PCR and MboII digestion (5). The silent mutation, T1317C, was identified by SSCP and sequence analysis in a patient with severe MTHFR deficiency and homocystinuria. This patient, an African- American female, already carries a previously-described splice mutation (patient 354 (8)). Since this mutation also creates a MboII site and results in a digestion pattern identical to that ofthe A1298C mutation, distinct artificially-created restriction sites were used to distinguish between these 2 mutations. Detection ofthe A1298C polymorphism was performed with the use ofthe sense primer 5 '-GGGAGGAGCTGACCAGTGC ACS' and the antisense primer (5'-GGGGTCAGGCCAGGGGCAG-3'), such that the 138bp PCR fragment was digested into 119bp and 19bp fragments by Fnu4HI in the presence of the C allele. An antisense primer (5'-GGTTCTCCCGAGAGGTAAAGATC-3') 5 which introduces a Taql site, was similarly designed to identify the C allele ofthe T1317C polymorphism. Together with a sense primer (5'-CTGGGGATGTGGTGGCACTGC- 3'), the 227bp fragment is digested into 202bp and 25bp fragments. Table 5 Genotype distributions, MTHFR activity (nmol formaldehyde/mg protein/hour), and total plasma homocysteine (tHcy;μM) for mothers and children Mothers (n=141) E/E E/A A/A A/A A/V V/V A/A A V V/V A/A A/V V/V # 24 32 19 27 26 0 13 0 0 % 17 23 13 19 18 0 9 0 0 MTHFR 49.0±18.9 33.0±10.8 15,7±4.5 45.0±16.0 30.2±19.3 - 32.1±9.0 [14] [19] * [11] * [15] [15] * [7] * THcy 9.5±3.1 10.0±3.2 12.2±7.1 8.4±2.1 10.0±3.1 - 9.5--2.0 [24] [32] [19] ** [25] [26] [13] Children (n=133) # 23 43 18 20 15 1 13 ( ) 0 % 17 32 13 15 11 1 10 0 0 MTHFR 52.0±17.0 38.2±15.0 16.2±5.3 35.7±9.7 26.1--5.0 21.6 29.5±10.3 - - [12] [27] * [11] * [18] * [9] * [1] [6] * THcy 7.6±2.5 8.2 ±3.0 9.7±5.1 7.5±2.3 8.1±2.8 9.5 7.4±1.5 - [23] [43] [18] ** [20] [15] [1] [13] The three A1298C genotypes and the three C677T genotypes are designated by the amino acid codes: EE, EA, AA, and AA, AV, VV, respectively. Statistical significance was assessed by student t-test, in comparison with EEAA values. * (p<0.0 5 ); ** (p_<0.07). Standard deviations are given and square brackets indicate the number of individuals for whom MTHFR activities and homocysteine levels were available. The frequencies ofthe three genotypes for the A1298C mutation (EE, EA and AA) were not different between case and control mothers, or between case and control children (data not shown). Consequently, all the mothers and all the children were grouped together for analyses (Table 5). Nine % of mothers had the homozygous AA genotype while 37% were heterozygous. This frequency is quite similar to the frequency ofthe homozygous mutant genotype (VV) for the C677T polymorphism. In the MTHFR human cDNA sequence mentioned above, the cDNA contained the C nucleotide at bp 1298 change as a C 1298 A substitution. Since the A nucleotide is clearly the more frequent base at this position, the A1298C nomenclature was chosen. Since the C677T mutation (A to N) decreases MTHFR activity and increases homocysteine levels, the three genotype groups for the A1298C (E to A) mutation were further stratified by the genotype for the A to N mutation, to avoid the confounding influence ofthe latter polymorphism on MTHFR activity and homocysteine levels. The frequencies ofthe 9 genotypes, with MTHFR activity and homocysteine levels for each genotype, are shown in Table 5. If the mothers and children without either mutation i.e. EE/AA are used as the reference (control) group, the mothers and children that are homozygous for the A1298C mutation (AAAA) have approximately 65% and 57%, respectively, of control MTHFR activity. Heterozygotes for the C677T change alone (EEAN) have approximately 70% of control activity, as reported in other studies, while double heterozygotes (EAAN), 18% of mothers and 11%) of children, have an additional loss of activity (approximately 62% and 50% of control values, respectively). Homocysteine levels were not significantly increased by the A 1298 C mutation, but homocysteine was elevated (with borderline significance, p<0.07) in mothers and children who were homozygous for the C677T change. The small number of individuals who were homozygous for the A1298C mutation (n=13) may have influenced the power ofthe statistical analyses and precluded an investigation ofthe genetic-nutrient interactive effect that leads to mild hyperhomocysteinemia, as seen in individuals with the C677T mutation. The T1317C substitution does not alter the amino acid (phenylalanine) and is likely a benign change, although a splicing defect cannot be ruled out at the present time. In an evaluation of 38 control mothers from this study, 2 were found to be heterozygous and one was identified as a homozygote, resulting in an allele frequency of 5% (4/76). Since this substitution was identified in an African- American female, control African individuals were also examined (n=9). Seven of these were heterozygous, resulting in an allele frequency of 39% (7/18). The A1298C mutation clearly reduces MTHFR activity, albeit to a lesser extent than the C677T mutation. Consequently its effect on homocysteine levels is also attenuated and, in fact, may only be significant when an individual carries both mutations and/or has poor nutrient status. However, since double heterozygotes are estimated to represent approximately 15% ofthe population, this variant should be examined in conjunction with the C677T variant in studies of hyperhomocysteinemia. The A1298C mutation is clearly polymorphic in Canadian individuals and should be examined in other populations. The A nucleotide is likely to be the ancestral sequence since it represents the more common allele, although the original human MTHFR cDNA sequence (GenBank accession number U09806) carried the C nucleotide. This polymorphism is similar in frequency to the C677T polymorphism. Presumably the two substitutions arose separately on a A1298/C677 or E/A haplotype, since the haplotype with both substitutions (C1298/T677 or A/V) is extremely rare. One such haplotype was seen in a child with the EANV genotype, suggesting a recombinant chromosome. Doubly homozygous individuals (AANN) were not observed in this study. Since the double mutation in cis is rare, it is possible that not enough alleles were studied. Larger studies in other populations might result in the identification of these individuals. Presumably the MTHFR activity would be even lower and homocysteine levels might be higher than those observed thus far. The C677T polymorphism in exon 4 is within the Ν-terminal catalytic domain ofthe enzyme whereas the A1298C polymorphism in exon 7 is within the C-terminal regulatory domain. The more dramatic effect on enzyme activity with the first polymorphism may be a consequence of its location within the catalytic region. The second polymorphism could affect enzyme regulation, possibly by S-adenosylmethionine, an allosteric inhibitor of MTHFR, which is known to bind in the C-terminal region. Many studies have examined the effects ofthe C677T polymorphism on MTHFR enzyme activity and on homocysteine levels. Although the correlation between the presence of this substitution and decreased enzyme activity/increased homocysteine levels has been quite good, the variability in results, particularly in heterozygous individuals, may reflect the presence of a second common variant in the population. The third variant, T1317C, was present on 5% of alleles in Canadian individuals but appears to be extremely common in individuals of African ancestry. The methodology outlined in this report should be used to assess the frequency ofthe A1298C and T1317C in other populations, since the use ofthe MboII restriction site for analysis of the A1298C change, as first reported, would not discriminate between the 2 polymorphisms. The C677T mutation is a risk factor for hyperhomocysteinemia and has been implicated in both neural tube defects and vascular disease. Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR) A human cDNA for MTHFR, 2.2 kb in length, has been expressed and shown to result in a catalytically-active enzyme of approximately 70 kDa. Fifteen mutations have been identified in the MTHFR gene: 14 rare mutations associated with severe enzymatic deficiency and one common variant associated with a milder deficiency. The common polymorphism has been implicated in three multifactorial diseases: occlusive vascular disease, neural tube defects and colon cancer. The human gene has been mapped to chromosomal region lp36.3 while the mouse gene has been localized to distal Chromosome 4. The isolation and characterization ofthe human and mouse genes for MTHFR is herein reported. A human genomic clone (17 kb) was found to contain the entire cDNA sequence of 2.2 kb; there were 11 exons ranging in size from 102 bp to 432 bp. Intron sizes ranged from 250 bp to 1.5 kb with one exception of 4.2 kb. The mouse genomic clones (19 kb) start 7 kb 5' to exon 1 and extend to the end ofthe coding sequence. The mouse amino acid sequence is approximately 90%> identical to the corresponding human sequence. The exon sizes, locations of intronic boundaries, and intron sizes are also quite similar between the two species. The availability of human genomic clones has been useful in designing primers for exon amplification and mutation detection. The mouse genomic clones may be used to make constructs for gene targeting and generation of mouse models for MTHFR deficiency. A common polymorphism, C677T has been identified, which converts an alanine codon to valine (Frosst et al., 1995). This common polymorphism, which is present on approximately 35% of alleles in the North American population, encodes the thermolabile variant and predisposes to mild hyperhomocysteinemia when folate status is low (Frosst et al., 1995; Jacques et al., 1996; Christensen et al., 1997). This genetic- nutrient interactive effect is believed to be a risk factor for arteriosclerosis (Frosst et al, 1995) and neural tube defects. In contrast, the mutant homozygous genotype may decrease the risk for colon cancer. The characterization ofthe genomic structure for human MTHFR is reported herein. The corresponding analysis ofthe mouse gene, with a comparison ofthe overall organization ofthe gene and the amino acid sequences in these two species, is also shown. Screening of genomic libraries Genomic libraries were screened using standard methods of plaque hybridization. The 2.2 kb human cDNA was radiolabelled and used as a probe in screening both human and murine genomic libraries. Screening for the human gene was performed on a phage library of partial EcoRI digestion fragments from total genomic DNA (ATCC # 37385), and on a phage library of chromosome 1 -specific complete EcoRI digestion fragments (ATCC# 57738). Screening for the mouse gene was performed on a λDASH library of partial Sau3A digestion fragments from total genomic DNA of mouse strain 129SN (obtained from Dr. J. Rossant, University of Toronto). Positive clones were purified by sequential rounds of screening and isolation, and phage DΝA was isolated using phage DΝA isolation columns (QIAGEN). Human clones were digested with EcoRI to release the inserts, and then with Xbal to facilitate cloning into Bluescript plasmid (Stratagene). The mouse clones were digested with Sail or EcoRI, and the inserts were subcloned into Bluescript. Characterization of mouse cDNA sequences Mouse genomic clones were sequenced (Sequenase kit, Amersham) using human cDNA primers spanning most ofthe available 2.2 kb cDNA. These sequences were then used to generate mouse-specific cDNA primers. The mouse-specific primers were used in PCR amplification of overlapping cDNA fragments from reverse-transcribed mouse liver RNA., The PCR products were subcloned into the PCRII vector (Invitrogen) and sequenced. Two different species of mouse (C57B1/6J and ct) were used to generate MTHFR sequence by RT-PCR, to ensure that the PCR protocol did not generate sequencing errors. Characterization of intron boundaries and sizes, and restriction analysis of human and mouse genes Primers from cDNA sequences of human and mouse were used to sequence the respective genomic clones. Intron boundaries were determined from regions of divergence between cDNA and genomic clone sequences, and by the identification of splice acceptor and donor consensus sites. Intronic sequences were obtained for 40-50 bp from the junctions and are shown in Figs. 12A-12B (human) and Figs. 13A-13B (mouse). The same cDNA primers were used in PCR amplification of total genomic DNA and of genomic clones to determine the approximate sizes of introns in the human and mouse genes. Table 6 lists the locations and approximate sizes of introns for both species. The PCR products were analyzed by restriction enzyme digestion to generate a preliminary restriction map ofthe gene. This restriction map was then confirmed by restriction analysis ofthe genomic clones in Bluescript. Referring to Figs. 12A-12B, the bp location ofthe exons within the cDNA, in parentheses, is based on the published human cDNA sequence (GenBank accession number U09806). Bp 1 is 12 bp upstream from the ATG in the original cDNA; an asterisk indicates the equivalent base here. Exon 1 contains the ATG start site (underlined), and exon 11 contains the termination codon (underlined). Uppercase characters indicate exonic sequences, and lower case characters are intronic. Consensus splice junction sequences are underlined. The 3' boundary of exon 11 has been designated by the location ofthe polyA tail. Referring to Figs. 13A-13B, the bp location ofthe exons within the cDNA, in parentheses, is based on the equivalent bp 1 ofthe human sequences in Figs. 12A-12B (bp 1 is indicated by an asterisk). Exon 1 contains the ATG start site (underlined), and exon 11 contains the termination codon (doubly underlined). Uppercase characters indicate exonic sequences, and lower case characters are intronic. Consensus splice junction sequences are underlined. The 3 ' boundary of exon 11 is designated as the termination codon, since the site of polyadenylation is unknown. Also underlined in exon 11 is the first repeat ofthe 52 bp repeated element. Referring to Fig. 14, exon sizes for human and mouse are reported in Figs. 12A-12B and Figs. 13A-13B, respectively. Exons are indicated in shaded boxes. Uncharacterized regions ofthe gene are hatched, and exon numbering corresponds to Figs. 12A-12B and 13A-13B. E=EcoRI; X=XbaI; A„=polyadenylation site. The EcoRI restriction site at the 5' end ofthe mouse gene is part ofthe phage polylinker sequence. Referring to Fig. 15, residues that are identical to the human MTHFR sequence are shown as empty boxes, and gaps in amino acid homology are represented by a dash. Human genomic clones The genomic clones isolated from the human libraries contained a 16 kb EcoRI fragment, encompassing part of exon 1 and exons 2 through 11, and a 1 kb EcoRI fragment containing most of exon 1. Exon 1 is defined as the most 5' exon from the previously published cDNA sequence; it contains the ATG start site that was used to express the human cDNA in bacterial extracts (Frosst et al. 1995). A graphic representation ofthe human gene and its restriction map are depicted in Fig. 3. The sequences of each exon and 50 bp of flanking intronic sequences are shown in Figs. 12A- 12B. Exons range in size from 102 bp to 432 bp, and the critical dinucleotides in the 5' and 3' splice site consensus sequences (GT and AG, respectively) are underlined. The 3' boundary of exon 11 is defined by the site of polyadenylation in the cDNA; a possible polyadenylation signal (AACCTA) is present 15 bp upstream ofthe polyadenylation site, although it varies from the consensus sequence. Table 6 lists the locations and approximate sizes of introns as determined by PCR amplification; the introns range in size from approximately 250 bp to 4.2 kb. Mouse genomic clones Genomic clones isolated from the mouse libraries were digested with EcoRI for subcloning and characterization. Exon nomenclature is based on the corresponding human gene sequences. Figs. 13 A-13B list all known exons and their sizes, with 40 to 50 bp of flanking intronic sequences. Fig. 14 shows a graphic representation ofthe mouse genomic structure aligned with the human gene. The size of exon 11 is undetermined, since the sequence for this region was determined directly from the genomic clones. The termination codon is located within a region of 52 bp which is repeated 3 times in the gene. The significance of this, if any, is unknown at the present time. The dinucleotides ofthe splice junctions (underlined in Figs. 13A-13B) are in agreement with consensus sequences. Table 6 lists the approximate sizes of introns as determined by PCR, and their bp location in the cDNA. The introns range in size from approximately 250 bp to 4.2 kb. Comparison ofthe human and mouse genes The human and mouse genes are very similar in size and structure (Fig. 14). The introns are similar in size, and identical in location within the coding sequence. However, the mouse cDNA is one amino acid shorter in exon 1 which causes a shift in bp numbering ofthe mouse cDNA (Table 6, Figs. 13A-13B). Exon 1 was defined from the original published human cDNA, based on the presence of a translation start codon. In both human and mouse genes, the 5' boundary of exon 1 was assigned after the isolation of several non-coding cDNA extensions that are generated by alternative splicing from this junction. Characterization of these 5' cDNA extensions is in progress. The nucleotide sequences ofthe human and mouse genes are very similar within coding regions, but homology decreases dramatically in the 3' UTR region and within introns. Human and mouse primary amino acid sequence homology The primary amino acid sequences of human and mouse were compared to each other, and aligned with the sequence ofthe MetF (MTHFR) enzyme from bacteria (Fig. 15). The human and mouse amino acid sequences are almost 90% identical. As previously observed, only the 5' half of the mammalian sequences align with the bacterial enzyme; bacterial MTHFR has the same catalytic activity as the mammalian enzyme but lacks the regulatory region in the C-terminal domain. The murine amino acid sequence is two amino acids shorter than the human sequence: one less amino acid in exon 1 and one less in exon 11. The isolation ofthe human MTHFR gene and the analysis of gene structure are part of an ongoing effort to study MTHFR deficiency in homocystinuria and in multifactorial diseases. The availability of genetic structure information and of intronic sequences will help in the mutational analysis of patients suffering from MTHFR deficiency and in the characterization ofthe 5' regulatory region. Expression analysis ofthe 2.2kb cDNA in a bacterial expression system resulted in a catalytically-active 70kDa protein (Frosst et al. 1995). A MTHFR polypeptide of this size was observed in some human tissues on Western blots, but a larger isozyme (77 kDa), corresponding to the estimated size ofthe porcine polypeptide, was observed in all the examined tissues. These data suggested the presence of protein isoforms for MTHFR that could be tissue-specific (Frosst et al., 1995). Since human or mouse sequences homologous to the N-terminal porcine amino acid sequences have not been identified, it is assumed that the missing sequences required to encode the larger isoform are 5' to the available cDNA sequences. Two mRNAs for human MTHFR (approximately 7.5 and 8.5 kb) have been seen in all tissues on Northern blots (data not shown), suggesting very large UTRs. The isolation of 5' coding sequences has been complicated by the presence of several alternatively-spliced 5 ' non-coding extensions that splice into exon 1. The alternative splicing into exon 1 has been observed in both human and mouse MTHFR. The long UTRs and the alternative splicing events suggest that the regulation of this important gene may be quite complex. Nonetheless, the available information has been critical for identification of mutations in patients with various forms of MTHFR deficiency. The mouse sequences in exons 1 and 2 have been useful in the design of antisense oligonucleotides to successfully inhibit MTHFR in mouse embryo cultures and disrupt development ofthe neural tube (Lanoue et al. 1997). The isolation and characterization of mouse genomic clones is essential for construction of targeting vectors to generate mouse models for MTHFR deficiency. Table 6: Approximate sizes of introns, and their locations in human and mouse MTHFR cDNA Approximate Human Mouse Intron size (kb) location 1 location 1 1 1.5 248-249 245-246 2 0.8 487-488 484-485 3 4.2 598-599 595-596 4 0.8 792-793 789-790 5 0.35 1043-1044 1040-1041 6 0.25 1178-1179 1175-1176 7 0.3 1359-1360 1356-1357 8 - 1.5 1542-1543 1539-1540 9 1.3 1644-1645 1641-1642 10 0.3 1764-1765 1761-1762 'Base pairs flanking introns, from Figs ;. 1 and 2. Bpl is 12 bp upstream from the ATG, as in the original report ofthe cDNA sequence (Goyette et al. 1994). Various doses of methotrexate (a drug used in treatment of cancer and arthritis, possibly other diseases) were added to colon carcinoma lines in culture. Much lower doses of methotrexate are needed to kill the lines that carry the 677C/T mutation in MTHFR, compared to lines that do not carry this mutation. The IC50 (concentration needed to kill half the cells) is approximately 20 nM for lines with the mutation and approximately 150 nM for lines without the mutation. To extrapolate to the human condition, patients with this MTHFR mutation might require lower doses of methotrexate for therapy, or might be subject to methotrexate toxicity at high doses. Table 7 Summary of BMD analysis Entire cohort: Values are means +/- SE Genotype 1/1 Genotype 1/2 Genotype 2/2 Spinal Z score -1.06 (0.193) -1.25 (0.176) -1.86 (0.238) Femoral neck Z score -0.69 (0.134) -0.78 (0.126) -0.87 (0.228) Trochanter Z score -0.60 (0.142) -0.52 (0.134) -1.15 (0.249) Ward's triangle Z score -0.67 (0.147) -0.80 (0.139) -0.96 (0.257) Table 7 indicates the values for bone mineral density in a group of individuals who were examined for the MTHFR C677T mutation. Genotype 1/1 = normal C/C Genotype 1/2 = earners C/T Genotype 2/2 = homozygons mutant T/T As seen on Table 7, the lower the score, the lower the bone mineral density and therefore the higher the risk for osteoporosis. The results suggest that the homozygons mutant genotype (2/2) is asssociated with lower bone mineral density and therefore higher risk of osteoporosis. Diagnosis and Therapeutic Outcome of a Psychosis MTHFR alleles are also useful as diagnostic, therapeutic, prognostic, and pharmacogenomic markers for neurological disorders such as psychoses and in other diseases and disorders that may be treated with anti-psychotic therapeutics. Psychoses are serious, debilitating mental illnesses which are characterized by loss of contact with reality and may also include any ofthe following symptoms: delusions, hallucinations, thought disorder, strange behavior or emotions, or withdrawal from social contact. The duration of untreated psychosis may be correlated with worsened patient-prognosis. Schizophrenia is the most common psychosis, which affects approximately 2 million Americans. Although genetic factors are known to play a role in the etiology of schizophrenia, identification of susceptibility genes has been difficult. This difficulty may be due partially to the variability ofthe schizophrenia phenotype, including variations in severity of symptoms, response to medications, and long-term outcome. Indeed, one third to one quarter of schizophrenic subjects remain severely symptomatic despite multiple trials with individual or combinations of anti-psychotic therapeutics, also called neuroleptics. This variability may reflect factors such as genetic heterogeneity or the presence of modifier genes. Compared to neuroleptic nonresponders, the group of responders is characterized by a high female to male ratio, better long-term outcome, and more frequently disturbed indices of dopamine neurotransmission. In addition to the inability to reduce symptoms in a substantial number of schizophrenia patients, current neuroleptic therapeutics also cause a variety of serious side effects. Examples ofthe adverse effects of conventional neuroleptics include cardiac conduction abnormalities can result in patient deaths, seizures, involuntary repetitive movements (tardive dyskinesia), dulling of cognition, sedation, weight gain, sexual or reproductive dysfunction, blood dyscrasias, jaundice, skin reactions such as uticaria and dermatitis, and extrapyramdial effects. Extrapyramdial side effects involve conditions such as abnormal facial expressions, restlessness or constant movement, and rigidity and tremor at rest (parkinsonian syndrome). Because ofthe severity of these side effects and the low therapeutic-to-toxic index of conventional neuroleptics, other neuroleptics, called atypical neuroleptics, have been recently developed. Atypical neuroleptics have a lower incidence of extrapyramidal symptoms and tardive dyskinesia; however, they are still associated with weight gain and effects on blood pressure and liver function, as observed for conventional neuroleptics. Due to the severity and heterogeneity of schizophrenia, improved methods are needed for diagnosing people at risk for or suffering from schizophrenia. Improved methods are also desirable for determining a preferred therapy for a particular diagnosed individual or group of individuals. The selection of a preferred therapy for a particular subject may prevent the subject from having to endure possibly irreversible side effects from therapies that are ineffective for that subject. Reduced side effects ofthe preferred therapy compared to other therapies may result in greater patient compliance, further increasing the likelihood of therapeutic benefit from the therapy. We have discovered that the heterozygous form ofthe C677T mutation in methylenetetrahydrofolate reductase (MTHFR) is more common in patients diagnosed with schizophrenia than in a healthy control population and thus is a risk factor for this disease. In addition, both the heterozygous and homozygous forms of this mutation are associated with an improved response to neuroleptic treatment and long-term outcome. Because the C677T mutation results in decreased MTHFR activity and increased enzyme thermolability, other MTHFR genotypes or haplotypes having similar characteristics may be associated with schizophrenia or improved response to neuroleptics. For example, another mutation of human MTHFR, A1298C which converts glutamic acid to alanine, also results in reduced activity in the encoded protein, and individuals who are heterozygous for both the C677T and A1298C mutations have even lower MTHFR activity and have higher homocysteine levels than observed in individuals with the single C677T mutation. Other similar mutations include, but are not limited to, G167A, G482A, C559T, C692T, C764T, a G/A G792+1A, C985T, C1015T, C1081T, T1317C, and any combination of these MTHFR mutations. In this study, two groups of schizophrenic patients selected on the basis of a priori defined criteria of long-term outcome and response to neuroleptics (excellent responders and very poor responders, Table 8) and a control group of health volunteers were compared with regard to the C-to-T substitution at nucleotide 677 ofthe MTHFR gene, called "N allele." Table 8 Demographic and clinical characteristics of patients and controls Nonresponders Responders (n=62) (n=43) Age (yr.) ± SD 38.7 + 6.9 40.6 + 10.5 Gender (% Males) 74 67 Age at 1 C (yr.) 18.1 ± 3.9 24.2 + 4.8 Subtype, U/P/D/C 26/30/4/1 6/36/1/0" Time as in-patient (%) 63.5 + 38 8.2 + 11.8 BPRS score 48.9 + 9.0 24.4 + 3.9 Age at 1 C = age at first contact with a psychiatric care facility, U = undifferentiated, P = paranoid, D= disorganized, C = catatonic, BPRS = Brief psychiatric rating scale. The heterozygous and homozygous C677T mutations were found more frequently in schizophrenia patients than in control subjects (Table 9). Table 9 Analysis of genotypic and allehc association of 677C— »T polymorphism in MTHFR gene. N of subjects with genotype (%) χ 2 statistic C vs. R Number of alleles (%) χ 2 statistic (df=l) (df=l). A/A V/A V/V A V All subjects C vs. R: χ 2 = 17.52, C 41 (44.5) 36 (40.0) 13 (14.4) D: χ 2 = 16.12, 117(65.0) 63 (35.0) p = 0.00003 p = 0.00006 R 5 (11.6) 23 (53.5) 15 (34.9) 33 (38.4) 53 (61.6) C vs. NR: χ 2 = 0.10, R: χ 2 = 7.49,p = 0.006 NR 25 (40.3) 29 (46.8) 8 (12.9) 79 (63.7) 45 (36.3) p = 0.74 00 Males C 17 (41.4) 18 (43.9) 6 (14.7) D: χ 2 = 14.0, p = 0.0001 53 (63.4) 30 (36.6) χ 2 = 12.77, p = 0.00035 R 1 (3.5) 17 (58.6) 11 (38.8) R: χ 2 = 5.01, p = 0.025 19 (32.7) 39 (67.3) Females C 24 (49.0) 18 (36.7) 7 (14.3) D: χ 2 = 2.02, p = 0.15 66 (67.3) 32 (32.7) χ 2 = 2.82, p = 0.092 R 4 (28.6) 6 (42.9) 4 (28.5) R: χ 2 = 1.63, p = 0.20 14 (50.0) 14 (50.0) D = dominant model, R = recessive model, C = controls, R = NLP responder patients, NR = NLP non responder patients. P- values are not corrected for multiples testing In addition, there was a significant association between schizophrenia and the presence of at least one C677T allele ofthe MTHFR gene (χ 2 = 5.44, degrees of freedom (df) = 1, p = 0.019). This association was due to an over-representation of allele N in neuroleptic responder patients compared to controls (χ 2 = 16.77, df = 1, p = 0.00004); non-responder patients did not differ from controls. In addition, the attributable fraction associated with carrying at least one N allele in the group of neuroleptic responder patients was 75%, meaning that 75% ofthe schizophrenia cases may be due to this mutation. The association between responder patients and the C677T mutation was statistically stronger in males than in females. The association between the C677T mutation and schizophrenia was observed for both a recessive (NN vs. AN+ AA) as well as a dominant model (NN + AV vs. AA) of transmission of this mutation; however, the latter showed consistently more power to discriminate between responsive patients and controls (Table 9). These results indicate that good response to neuroleptic medication and good long-term outcome characterize the schizophrenia phenotype associated with allele V of the MTHFR gene. The fact that no association with the V allele was observed in the groups of neuroleptic nonresponder patients indicates, as previously suggested, that these two groups of patients are at least partially different from a pathogenic point of view. The dosage effect of allele V on age-at-onset, a marker of severity of illness that is independent from responsiveness to neuroleptics, suggests that this association is possibly mediated by a schizophrenia subtype. Thus, the classification of schizophrenic patients by the presence or absence ofthe C677T mutation may be an effective strategy to reduce heterogeneity for studies ofthe treatment or biology of schizophrenia. Additionally, the association of allele V with the ability of neuroleptic treatment to reverse psychotic symptoms and possibly the deterioration associated with untreated psychosis may be due to the association of allele V with an ability to respond to neuroleptics that is independent of schizophrenia subtype. While not meant to limit the invention to a particular theory, it also possible the V allele is associated with a disturbance in the one-carbon cycle metabolism regulated by MTHFR, since MTHFR provides the carbon group for the generation of S-adenosylmethionine, a universal methyl donor. A disturbance of one-carbon metabolism may result in a deficiency of methylation reactions that are required for numerous pathways including, detoxification, DNA methylation and regulation of biogenic amine metabolism. Another possibility is that the V allelic variant may act as a moderator ofthe severity of schizophrenia by increasing the plasma concentration of homocysteine. Indeed it has been reported that a homocysteine load causes worsening of psychotic symptoms in schizophrenic patients. The association of other MTHFR alleles with schizophrenia, or any other disease, or with response to particular therapies may be determined by any standard methods (see, for example, those methods described in WO 00/04194; Ueda et al, Circulation 98:2148- 2153, 1998, Tan et al, Lancet 350:995-999, 1997; Poirier et al, Proc. Natl. Acad. Sci. USA 92:12260-12264, 1995; Spire-Vayron de la Moureyre et al, British J. of Pharmacology 125:879-887, 1998; Drazen et /., Nature Genetics 22:168-170, 1999; Smeraldi et al, Molecular Psychiatry 3:508-511, 1998; Kuivenhoven et al. New Eng. J. of Med. 338(2):86-93, 1998; Aarranz et al, Molecular Psychiatry 3:61-66, 1998). Haplotyping may also be used to determine associations between particular mutations or combination of mutations and particular diseases or responses to particular therapies. Clinical trials for an anti-psychotic therapy may be conducted as described below or using any other appropriate method. The subjects in the trial may be stratified based upon their MTHFR genotype at the relevant polymorphic sites. This stratification may be used to correlate an MTHFR genotype or haplotype with the efficacy or the safety ofthe therapy and may be performed before, during, or after the clinical trial. The correlation of the safety and efficacy ofthe therapy in subjects with a particular MTHFR mutation or combination of MTHFR mutations may be considered during the Food and Drug Administration (FDA) approval process and used to determine preferred therapies for the different MTHFR subgroups of subjects. Briefly, clinical trials generally consist of four phases: Phase I is a safety study generally involving healthy volunteers; Phase II is a dose-ranging, efficacy study involving subjects diagnosed with a condition, and Phase III is a larger safety and efficacy study. If the efficacy data from the Phase III trial are statistically significant, the therapy may be approved by the FDA. Phase IV is a post-marking approval trial that may be used to further refine the approved indication population or to compare one therapy to another one. This process for testing a therapy in humans may also be modified by one skilled in the art depending on specific pharmacokinetic or pharmacodynamic properties ofthe therapy or the availability of subjects diagnosed with the condition. For example, cytotoxic therapies, such as cancer chemotherapeutics, are not tested in healthy control subjects and generally begin clinical trials with a Phase 11 study. Clinical trials may be performed using standard protocols(see, for example, Spilker, Guide to Clinical Trials, Raven Press, 1991; Tygstrup, ed., The Randomized Clinical Trial and Therapeutic Decisions Marcel Dekker; Thall, ed. Recent Advances in Clinical Trial Design and Analysis, Cancer Treatment and Research, Ctar 75, Kluwer Academic, 1995; and Piantadosi, Clinical Trials: A Methodologic Perspective, Wiley Series in Probability and Statistics, 1997). Examples of possible clinical trials protocols include placebo-controlled, single blinded, double blinded, crossover, and other studies. For the design of clinical trials to test the contribution of an MTHFR mutation or a combination of MTHFR mutations to variation in patient response to a therapy, one skilled in the art may use readily available methods to determine the appropriate parameters for a particular clinical trial. Examples of such factors include the genetic hypothesis to be tested, the number of subjects required to observe a statistically significant effect (power analysis), the appropriate dosing range, the duration ofthe trial, and the appropriate endpoints to measure the response to the therapy. The applications of genetic hypothesis testing, power analysis, and statistical analysis of patient response to each phase of a clinical trial have been described previously. Additionally, haplotyping may be used to detect which MTHFR genotype at which position may be correlated with a particular response to a particular therapy. The endpoints of a clinical trial of an anti-psychotic therapy may include factors associated with the conditions. Examples of possible endpoints include semi-objective grading scales administered by clinical staff. Several standard grading scales have been developed and accepted as assessment tools ofthe efficacy of a therapy in clinical trials and include, but are not limited to, cognitive assessment, pain, psychotic, behavioral, and global clinical impression scales. A further consideration for the design of a clinical trial for a compound in the category of psychiatric illness is the duration ofthe trial. It may take weeks to months before a "wash-out" can be achieved (i.e. reduction ofthe dose to the point of removal of therapy) for the therapies that the subjects had been receiving prior to the clinical trial. Additionally, many anti-psychotics exhibit dose-dependent efficacy and often require 2-3 weeks before empirical clinical global impression and semi-objective grading scale analysis suggests a therapeutic dose has been achieved. Both the "run-in" period for the achievement of a therapeutic dose and the "run-out" period for the subsequent decrease in the dose for removal ofthe therapy after the clinical trial must be performed under controlled conditions. The present invention provides a number of advantages. For example, the methods described herein allow for the determination of a subject at risk for a psychosis for the timely administration of a prophylactic therapy to prevent or delay the psychosis. Thus, this determination of increased risk for a psychosis may occur before the presence of debilitating symptoms that might otherwise be required for a definitive diagnosis. The methods ofthe invention also have the advantage of only requiring the presence of one mutation in one MTHFR allele instead of requiring a homozygous mutation for the association ofthe mutation with a psychosis; this is a particular advantage in the diagnosis of schizophrenia which was previously correlated exclusively with homozygous patient genotypes. Additionally, the presence of mutations in MTHFR alleles may be easily and rapidly determined using standard techniques. Moreover, the administration of a preferred therapy to subject at risk for or diagnosed with from a psychosis may result in improved patient-outcome, improved drug-efficacy, or reduced drug-toxicity compared to the administration of other therapies. These results may reduce healthcare costs by decreasing the number of required doctor visits or hospitalizations. The following example is provided to illustrate the invention. It is not meant to limit the invention in any way.' Association of the C677T MTHFR mutation with schizophrenia, response to therapy, and long-term outcome Selection of patients Nonresponding schizophrenic patients (NR, n = 43) were selected from a list of schizophrenic patients identified as candidates for treatment or treated with atypical neuroleptics because of treatment resistance to conventional neuropleptics. Three institutions provided these NR patients: Douglas Hospital, Clinique Jeunes Adultes of L.H. Lafontaine Hospital, and the Schizophrenia Clinic ofthe Royal Ottawa Hospital. Responding patients (R, n= 62) were selected from a list of all patients who were considered very good responders to conventional neuroleptics by their treating physician and/or nurse and who were followed in the outpatient clinics attached to the Douglas and L.H. Lafontaine hospitals, which are the only two university-affiliated psychiatric hospitals for the Montreal intra-muros region. The following criteria for response or resistance to conventional neuroleptics were used in the selection of NR schizophrenic patients. None ofthe NR patients had experienced remission of psychotic symptoms within the past two years. In the preceding five years, all NR patients had undergone at least three periods of treatment with conventional neuroleptics from at least two distinct families of drugs at a dose equal to, or greater than, 750 mg chlorpromazine (CPZ) equivalents for monotherapy or 1000 mg CPZ for therapy with a combination of neuroleptics. The treatments, which lasted for a continuous period of at least 6 weeks, resulted in no significant decrease in symptoms. Finally, all patients were unable to function without supervision in all, or nearly all, domains of social and vocational activities and had a Global Assessment Score (GAS) (Endicott et al. , Arch. Gen. Psychiatry 33.766-771, 1976) greater than 40 within the last 12 months. Decision for non-response was established by the research psychiatrist upon review of medical records, with particular attention to: (i) unusual thought content, (ii) hallucinations, (iii) conceptual disorganization, (iv) motor retardation, and (v) emotional withdrawal (items 3, 4, 12, 13 and 15 ofthe Brief Psychiatric Rating Scale; BPRS) (Woerner et α/. , Psychopharmacol. Bull. 24:112-117, 1988). At the time of emoUment, a minimal score of 4 (moderate to severe) on at least three ofthe five BPRS items (3, 4, 12, 13, 15), a total BPRS score of at least 45 and/or a CGI (Clinical global Impression) score of at least 5 (markedly ill) were required. These criteria for treatment resistance were derived from those of Kane et al. (Arch. Gen. Psychiatry 45(9):789-96, 1988). Among the selected R patients, all patients had been admitted at least once to a psychiatric institution because of an acute psychotic episode. During each hospitalization, patients experienced a full or partial remission in response to treatment with conventional neuroleptics within 6 to 8 weeks of continuous treatment. All patients were able to function autonomously with only occasional supervision in all, or nearly all, domains of social and vocational activities. None ofthe R patients had to be admitted to hospitals because of psychotic exacerbation while under continuous neuroleptic treatment. All R patients had at least one psychotic relapse when neuroleptic medication was reduced or discontinued. Remission was defined as a complete or quasi-complete disappearance of schizophrenic symptoms, with limited residual symptoms, based on the treating psychiatrist clinical evaluation and hospital records. At the time of enrollment, total BPRS scores were less than 30 with no more than one item scoring 4 and/or a CGI score less than 3 (borderline mentally ill). Both NR and R patients were directly interviewed using the Diagnostic Interview for Genetic Studies (DIGS) (Nurnberger et al, Arch. Gen. Psychiatry 51:849-859, 1994), and their medical records were comprehensively reviewed by a research psychiatrist. Complementary information from the treating physician and nurses in charge was also obtained. The severity ofthe clinical syndrome at the time of examination was evaluated by the BPRS, and the diagnosis as meeting the criteria for NR or R patients was based on all the available data. The 90 control patients (C) were determined not to have any DSM-IV axis I mental disorders based on DIGS. All subjects were Caucasian with a majority (52 %) of French Canadians. This project was approved by the Research Ethics Board of each participating institution. Genetic analysis Genomic DNA was isolated from peripheral lymphocytes using standard methods. The target sequence was amplified by PCR using the published procedure of Frosst et al. (Nat. Genet. 10(1): 111-113, 1995). PCR products were digested with Hinfl because the C677T mutation creates a Hinfl recognition sequence. The PCR product of 198 bp was digested into fragments of 175 bp and 23 bp if the C677T mutation was present, while the wild-type (alanine) allele remained undigested (198 bp). The digested PCR products were elecfrophoresed on 9% polyacrylamide gels and photographed. Genotyping and scoring were performed by someone blinded to the diagnosis. Statistical analysis The allele frequencies in the groups of schizophrenia subjects and confrols were compared using a Chi square statistic with one degree of freedom. Because a statistically significant difference between patients and controls was observed in the frequency of allele V, pair- wise comparisons between the three groups of subjects (R, NR, and C) were subsequently conducted. To test for a population bias within the subjects tested, an analysis between the R, NR, and C patients for whom both parents were French Canadian and for whom at least one parent did not have French Canadian ancestry was also performed. Comparison of responding, nonresponding, and control groups based on frequence ofthe C677T MTHFR allele R and NR schizophrenic patients did not differ significantly according to age and gender distributions. Controls were significantly older and included more females than the R and NR groups. In keeping with the study design, the two groups of schizophrenia patients differed significantly according to the severity of psychosis, the percent of time spent as inpatient since their first contact with a psychiatric institution, and their age at first contact with psychiatric care facilities (Table 8). Allele V was significantly more frequent in schizophrenic patients, regardless of the quality of their response to neuroleptics and long-term outcome, compared to controls (χ 2 = 5.44, df = 1, p = 0.019). However, the most striking finding was observed when patients were stratified according to their quality of response to conventional neuroleptics and long-term outcome. The group of R patients showed a highly significant increase in the frequency of allele V (χ 2 = 16.77, df = 1, p = 0.00004) in contrast to the group of NR patients (χ 2 = 0.053, df = 1, p = 0.81). The odds ratio associated with carrying at least one allele V in the group of responder patients was 6.80 with a 95% confidence interval of 5.22 to 8.87. The same pattern of differences between responders and confrols was observed when subjects with two French Canadian parents (χ 2 = 8.91, df = 1, p = 0.002) and those with at least one non-French Canadian parent (χ = 6.71 , df = 1 , p = 0.009) were compared separately;. The similar results observed in both subpopulations compared to the overall tested Caucasian population reduces the likelihood of a population stratification bias in the data. The stratification ofthe data according to gender resulted in a significant difference in males (χ 2 = 12.63, df = 1, p = 0.0003) and a trend in females (χ 2 = 2.58, df= I. p = 0.10). Both dominant (VN + AV vs. AA) and recessive (VV vs. AV+ AA) models of transmission ofthe C677T mutation were tested. For both models, the differences between neuroleptic responder patients and controls were significant for the whole group of patients and for the groups stratified according to background of parents (Table 9). Finally, an AΝOVA analysis was performed in which the genotype was the grouping variable and the age-at-onset was the outcome variable. A tendency toward a dose effect of allele V was observed for the age-at-onset (F = 2.48, df = (2, 94); p = 0.088). The average ages at onset ± (SD) were 19.16 (4.49), 20.91 (5.42) and 22.52 (5.53) for patients with genotypes AA, AV, and VV respectively. Other Embodiments While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations ofthe invention following, in general, the principles ofthe invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope ofthe appended claims.

Claims: CLAIMS 1. A method of diagnosing a psychosis in a subject, said method comprising the steps of: i (a) analyzing the methylenetetrahydrofolate reductase (MTHFR) nucleic acid in a sample obtained from said subject; and (b) determining the presence of at least one heterozygous MTHFR mutant allele in said subject, wherein the presence of said mutant allele is indicative of said subject having said psychosis. 2. The method of claim 1, wherein said psychosis is schizophrenia. 3. The method of claim 1, wherein said mutant allele encodes an MTHFR protein with reduced activity or reduced thermal stability. 4. The method of claim 1, wherein said mutant allele comprises a G/A mutation at position 167, a G/A mutation at position 482, a C/T mutation a position 559, a C/T mutation at position 677, a C/T mutation at position 692, a C/T mutation at position 764, a G/A mutation at position 792+1, a C/T mutation at position 985, a C/T mutation at position 1015, a C/T mutation at position 1081, an A/C mutation at position 1298, or a T/C mutation at position 1317. 5. The method of claim 4, wherein said mutant allele comprises a C/T mutation at position 677 or an A/C mutation at position 1298. 5 6. A method of determining a risk for a psychosis or propensity thereto in a subject, said method comprising the steps of: (a) analyzing the MTHFR nucleic acid in a sample obtained from said subject; and (b) determining the presence of at least one heterozygous MTHFR mutant allele in 0 said subject, wherein the presence of said mutant allele is indicative of a risk for a psychosis or propensity thereto in said subject. 7. The method of claim 6, wherein said psychosis is schizophrenia. 8. The method of claim 6, wherein said mutant allele encodes an MTHFR protein with reduced activity or reduced thermal stability. 9. The method of claim 6, wherein said mutant allele comprises a G/A mutation at position 167, a G/A mutation at position 482, a C/T mutation a position 559, a C/T mutation at position 677, a C/T mutation at position 692, a C/T mutation at position 764, a G/A mutation at position 792+1, a C/T mutation at position 985, a C/T mutation at position 1015, a C/T mutation at position 1081 , an A/C mutation at position 1298, or a T/C mutation at position 1317. 10. The method of claim 9, wherein said mutant allele comprises a C/T mutation at position 677 or an A/C mutation at position 1298. 11. A method of diagnosing a psychosis in a subject, said method comprising the steps of: (a) analyzing the MTHFR nucleic acid in a sample obtained from said subject; and (b) determining the presence of a heterozygous MTHFR mutation at position 677 and the presence of at least one other MTHFR mutation at a position other than 677, wherein the presence of said mutations is indicative of said subject having said psychosis. 12. The method of claim 11, wherein said psychosis is schizophrenia. 13. The method of claim 11 , wherein said mutant MTHFR nucleic acid encodes a protein having reduced activity or reduced thermal stability. 14. The method of claim 11, wherein said mutant MTHFR nucleic acid comprises a G/A mutation at position 167, a G/A mutation at position 482, a C/T mutation a position 559, a C/T mutation at position 677, a C/T mutation at position 692, a C/T mutation at position 764, a G/A mutation at position 792+1, a C/T mutation at position 985, a C/T mutation at position 1015, a C/T mutation at position-108-l-an-A Θ- mutatio atposition — 1298, or a T/C mutation at position 1317. 15. The method of claim 14, wherein said mutant MTHFR nucleic acid comprises a C/T mutation at position 677 or an A C mutation at position 1298. 16. A method of diagnosing a risk for a psychosis or propensity thereto in a subject, said method comprising the steps of: (a) analyzing the MTHFR nucleic acid in a sample obtained from said subject; and (b) deterrrώiing the presence of a heterozygous MTHFR mutation at position 677 and the presence of at least one other MTHFR mutation at a position other than 677, wherein the presence of said mutations is indicative of a risk for a psychosis or propensity thereto in said subject. 17. The method of claim 16, wherein said psychosis is schizophrenia. 18. The method of claim 16, wherein said mutant MTHFR nucleic acid encodes a protein having reduced activity or reduced thermal stability. 19. The method of claim 16, wherein said mutant MTHFR nucleic acid comprises a G/A mutation at position 167, a G/A mutation at position 482, a C/T mutation a position 559, a C/T mutation at position 677, a C/T mutation at position 692, a C/T mutation at position 764, a G/A mutation at position 792+1, a C/T mutation at position 985, a C/T mutation at position 1015, a C/T mutation at position 1081, an A/C mutation at position 1298, or a T/C mutation at position 1317. 20. The method of claim 19, wherein said mutant MTHFR nucleic acid comprises a C/T mutation at position 677 or an A/C mutation at position 1298. 21. A method for stratification of subjects involved in a clinical trial of an anti- psychotic therapy, said method comprising analyzing the MTHFR nucleic acid in a sample obtained from said subject and determining the presence of at least one MTHFR mutant allele in said subject before, during, or after said clinical trial, wherein the presence of said mutant allele in said subject places said subject into a subgroup for said clinical trial. 22. The method of claim 21, wherein said anti-psychotic therapy is a therapy for schizophrenia. 23. The method of claim 21, wherein said mutant allele encodes an MTHFR protein with reduced activity or reduced thermal stability. 24. The method of claim 21, wherein said mutant allele comprises a G/A mutation at position 167, a G/A mutation at position 482, a C/T mutation a position 559, a C/T mutation at position 677, a C/T mutation at position 692, a C/T mutation at position 764, a G/A mutation at position 792+1 , a C/T mutation at position 985, a C/T mutation at position 1015, a C/T mutation at position 1081, an A/C mutation at position 1298, or a T/C mutation at position 1317. 25. The method of claim 24, wherein said mutant allele comprises a C/T mutation at position 677 or an A/C mutation at position 1298. 26. The method of claim 21 , wherein said subj ect comprises at least two MTHFR mutant alleles. 27. The method of claim 26, wherein said mutant alleles comprise at least one of a G/A mutation at position 167, a G/A mutation at position 482, a C/T mutation a position 559, a C/T mutation at position 677, a C/T mutation at position 692, a C/T mutation at position 764, a G/A mutation at position 792+1, a C/T mutation at position 985, a C/T mutation at position 1015, a C/T mutation at position 1081, an A/C mutation at position 1298, or a T/C mutation at position 1317. 28. The method of claim 27, wherein said mutant alleles comprise-at least one of a C/T mutation at position 677 or an A/C mutation at position 1298. 29. A method for selecting a therapy for a subject suffering from a psychosis, said i method comprising the steps of: (a) analyzing the MTHFR nucleic acid in a sample obtained from said subject; and (b) determining the presence of at least one MTHFR mutant allele in said subject, wherein the presence of said mutant allele is indicative ofthe safety or efficacy of said therapy. 30. The method of claim 29, wherein said psychosis is schizophrenia. 31. The method of claim 29, wherein said mutant allele encodes an MTHFR protein with reduced activity or reduced thermal stability. 32. The method of claim 29, wherein said mutant allele comprises a G/A mutation at position 167, a G/A mutation at position 482, a C/T mutation a position 559, a C/T mutation at position 677, a C/T mutation at position 692, a C/T mutation at position 764, a G/A mutation at position 792+1, a C/T mutation at position 985, a C/T mutation at position 1015, a C/T mutation at position 1081, an A/C mutation at position 1298, or a T/C mutation at position 1317. 33. The method of claim 32, wherein said mutant allele comprises a C/T mutation at position 677 or an A/C mutation at position 1298. 34. The method of claim 29, wherein said subject comprises at least two MTHFR mutant alleles. 35. The method of claim 34, wherein said mutant alleles comprise at least one of a G/A mutation at position 167, a G/A mutation at position 482, a C/T mutation a position 559, a C/T mutation at position 677, a C/T mutation at position 692, a C/T mutation at position 764, a G/A mutation at position 792+1, a C/T mutation at position 985ra C/T mutation at position 1015, a C/T mutation at position 1081, an A/C mutation at position 1298, or a T/C mutation at position 1317. 36. The method of claim 35, wherein said mutant alleles comprise at least one of a C/T mutation at position 677 or an A/C mutation at position 1298. 37. A method for determining whether a mutant MTHFR allele is indicative of a response to a therapy for a psychosis, said method comprises the steps of: (a) determining whether said response of a first subject or set of subjects at increased risk for or diagnosed with said psychosis differs from said response of a second subject or set of subjects at increased risk for or diagnosed with said psychosis; (b) analyzing the MTHFR nucleic acid in a sample obtained from said first subject or set of subjects and said second subject or set of subjects; and (c) determining whether at least one MTHFR mutant allele differs between said first subject or set of subjects and said second subject or set of subjects, wherein the presence of said mutant allele is correlated to said response, thereby determining whether said mutant allele is indicative ofthe safety or efficacy of said therapy. 38. The method of claim 37, wherein said psychosis is schizophrenia. 39. The method of claim 37, wherein said mutant allele encodes an MTHFR protein with reduced activity or reduced thermal stability. 40. The method of claim 37, wherein said mutant allele comprises a G/A mutation at position 167, a G/A mutation at position 482, a C/T mutation a position 559, a C/T mutation at position 677, a C/T mutation at position 692, a C/T mutation at position 764, a G/A mutation at position 792+1, a C/T mutation at position 985, a C/T mutation at position 1015, a C/T mutation at position 1081, an A C mutation at position 1298, or a T/C mutation at position 1317. 41. The method of claim 40, wherein said mutant allele comprises a C/T mutation at position 677 or an A/C mutation at position 1298. 42. The method of claim 37, wherein said subject comprises at least two MTHFR mutant alleles. 43. The method of claim 42, wherein said mutant alleles comprise at least one of a G/A mutation at position 167, a G/A mutation at position 482, a C/T mutation a position 559, a C/T mutation at position 677, a C/T mutation at position 692, a C/T mutation at position 764, a G/A mutation at position 792+1 , a C/T mutation at position 985, a C/T mutation at position 1015, a C/T mutation at position 1081, an A/C mutation at position 1298, or a T/C mutation at position 1317. 44. The method of claim 43, wherein said mutant alleles comprise at least one of a C/T mutation at position 677 or an A C mutation at position 1298. 45. A method for preventing, delaying, or treating a psychosis in a subject, said method comprising the steps of: (a) analyzing the MTHFR nucleic acid in a sample obtained from said subject; (b) determining the presence of at least one MTHFR mutant allele in said subject, wherein the presence of said mutant allele is predictive ofthe safety or efficacy of at least one anti-psychotic therapy; (c) determining a preferred therapy for said subject; and (d) administering said preferred therapy to said subject. 46. The method of claim 45, wherein said psychosis is schizophrenia. 47. The method of claim 45, wherein said mutant allele encodes an MTHFR protein with reduced activity or reduced thermal stability. 48. The method of claim 45, wherein said mutant allele comprises a G/A ~ mutation at position 167, a G/A mutation at position 482, a C/T mutation a position 559, a C/T mutation at position 677, a C/T mutation at position 692, a C/T mutation at position 764, a G/A mutation at position 792+1, a C/T mutation at position 985, a C/T mutation at position 1015, a C/T mutation at position 1081, an A/C mutation at position 1298, or a T/C mutation at position 1317. 49. The method of claim 48, wherein said mutant allele comprises a C/T mutation at position 677 or an A/C mutation at position 1298. 50. The method of claim 45, wherein said subject comprises at least two MTHFR mutant alleles. 51. The method of claim 50, wherein said mutant alleles comprise at least one of a G/A mutation at position 167, a G/A mutation at position 482, a C/T mutation a position 559, a C/T mutation at position 677, a C/T mutation at position 692, a C/T mutation at position 764, a G/A mutation at position 792+1, a C/T mutation at position 985, a C/T mutation at position 1015, a C/T mutation at position 1081, an A/C mutation at position 1298, or a T/C mutation at position 1317. 52. The method of claim 51, wherein said mutant alleles comprise at least one of a C/T mutation at position 677 or an A/C mutation at position 1298. 53. A pharmaceutical composition comprising a compound which has a differential effect in subjects having at least one copy of a particular MTHFR allele; and a pharmaceutically acceptable carrier or excipient or diluent, wherein said composition is preferentially effective to treat a subject having said MTHFR allele. 54. The method of claim 53-, wherein said composition is adapted to be preferentially effective based on the unit dosage, presence of additional active components, complexing of said compound with stabilizing components, or inclusion of components enhancing delivery or slowing excretion of said compound. 55. The composition of claim 53, wherein said compound is deleterious to subjects having at least one said MTHFR allele or in subjects not having at least one said MTHFR allele, but not in both. 56. The composition of claim 53, wherein said subject suffers from a disease or condition selected from the group consisting of amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, psychoses, and stroke. 57. The pharmaceutical composition of claim 53, wherein said composition is subject to a regulatory restriction or recommendation for use of a diagnostic test determining the presence or absence of at least one said MTHFR allele. 58. The pharmaceutical composition of claim 53, wherein said pharmaceutical composition is subject to a regulatory limitation or recommendation restricting or recommending restriction ofthe use of said pharmaceutical composition to subjects having at least one said MTHFR allele. 59. The pharmaceutical composition of claim 53, wherein said pharmaceutical composition is subject to a regulatory limitation or recommendation indicating said pharmaceutical composition is not to be used in subjects having at least one said MTHFR allele. 60. The pharmaceutical composition of claim 53, wherein said pharmaceutical composition is packaged, and the packaging includes a label or insert restricting or recommending the restriction ofthe use of said pharmaceutical composition to subjects having at least one said MTHFR allele. 61. The pharmaceutical composition of claim 53 , wherein said pharmaceutical composition is packaged, and said packaging includes a label or insert requiring or recommending the use of a test to determine the presence or absence of at least one said MTHFR allele in a subject. 62. The pharmaceutical composition of claim 53, wherein said compound is an anti-psychotic therapy. 63. The pharmaceutical composition of claim 62, wherein said compound is a therapy for schizophrenia. 64. The pharmaceutical composition of claim 53, wherein said MTHFR allele encodes an MTHFR protein with reduced activity or reduced thermal stability. 65. The pharmaceutical composition of claim 53, wherein said MTHFR allele comprises a G/A mutation at position 167, a G/A mutation at position 482, a C/T mutation a position 559, a C/T mutation at position 677, a C/T mutation at position 692, a C/T mutation at position 764, a G/A mutation at position 792+1, a C/T mutation at position 985, a C/T mutation at position 1015, a C/T mutation at position 1081, an A/C mutation at position 1298, or a T/C mutation at position 1317. 66. The pharmaceutical composition of claim 53, wherein said MTHFR allele comprises a C/T mutation at position 677 or an A/C mutation at position 1298. 67. The pharmaceutical composition of claim 53, wherein said subject comprises at least two MTHFR mutant alleles. 68. The pharmaceutical composition of claim 67, wherein said mutant MTHFR alleles comprise at least one of a G/A mutation at position 167, a G/A mutation at position 482, a C/T mutation a position 559, a C/T mutation at position 677, a C/T mutation at position 692, a C/T mutation at position 764, a G/A mutation at position 792+1, a C/T mutation at position 985, a C/T mutation at position 1015, a C/T mutation at position 1081, an A/C mutation at position 1298, or a T/C mutation at position 1317. 69. The pharmaceutical composition of claim 67, wherein said mutant MTHFR alleles comprise at least one of a C/T mutation at position 677 or an A/C mutation at position 1298.

Inventors: ROZEN RIMA, ROZEN, RIMA
Applicants: UNIV MCGILL, MCGILL UNIVERSITY
Application year: 2001
Main classification: C12Q1
IPC codes: A61K45, A61P7, A61P9, A61P25, C12N15, C12Q1